[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 617
1. Lakhan SE, Harle L: Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature. J Med Case Rep; 2009;3:87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature.
  • The diagnosis of a high-grade brainstem glioma is usually reached due to the presentation of rapidly progressing brainstem, cranial nerve and cerebellar symptoms.
  • At autopsy, a high-grade invasive pontine tumor was identified.
  • While radiographic findings are often suggestive of the underlying pathology, this case represents the possibility of glioblastoma multiforme presenting as a deceptively benign appearing lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Cancer. 2004 Oct-Dec;41(4):170-4 [15659871.001]
  • [Cites] Pediatr Radiol. 1998 Aug;28(8):575-9 [9716624.001]
  • [Cites] No To Shinkei. 1997 Jun;49(6):547-51 [9198096.001]
  • [Cites] J Med Assoc Thai. 1996 Jun;79(6):403-8 [8855617.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):24-34 [8817612.001]
  • [Cites] Pediatr Radiol. 2006 Sep;36(9):959-64 [16847598.001]
  • [Cites] Neurosurg Clin N Am. 1993 Jul;4(3):529-36 [8353450.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1294-6 [6277461.001]
  • [Cites] Acta Neurochir (Wien). 2002 Sep;144(9):941-4; discussion 944-5 [12376778.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] CA Cancer J Clin. 1993 Sep-Oct;43(5):272-88 [8364769.001]
  • (PMID = 19946563.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783086
  •  go-up   go-down


2. Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, Flickinger JC: Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery; 2008 Jan;62(1):53-8; discussion 58-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Stereotactic radiosurgery has become an important primary or adjuvant minimally invasive management strategy for patients with intracranial meningiomas with the goals of long-term tumor growth prevention and maintenance of patient neurological function.
  • We evaluated clinical and imaging outcomes of meningiomas stratified by histological tumor grade.
  • Tumor locations included middle fossa (n = 351), posterior fossa (n = 307), convexity (n = 126), anterior fossa (n = 88), parasagittal region (n = 113), or other (n = 115).
  • RESULTS: The overall control rate for patients with benign meningiomas (World Health Organization Grade I) was 93%.
  • In those without previous histological confirmation (n = 482), tumor control was 97%.
  • However, for patients with World Health Organization Grade II and III tumors, tumor control was 50 and 17%, respectively.
  • After 10 years, Grade 1 tumors were controlled in 91% (n = 53); in those without histology, 95% (n = 22) were controlled.
  • None of the patients developed a radiation-induced tumor.
  • CONCLUSION: Stereotactic radiosurgery provided high rates of tumor growth control or regression in patients with benign meningiomas with low risk.
  • This study confirms the role of radiosurgery as an effective management choice for patients with small to medium-sized symptomatic, newly diagnosed or recurrent meningiomas of the brain.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300891.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL, Hong YR: Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep; 2010 Nov;24(5):1225-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors.
  • However, the role of Hh signaling components and Snail/E-cadherin in brain tumors is not yet fully understood.
  • We analyzed the expression of Hh signaling components and Snail/E-cadherin in 69 brain tumors by reverse transcription-polymerase chain reaction (RT-PCR).
  • The data showed that overexpression of Smo (35/69), Ptch (50/69), Gli1 (56/69), Gli2 (29/69) and N-myc (39/69) might contribute to brain tumorigenesis.
  • Our results also indicated that Snail and E-cadherin showed opposing expression in malignant tumors (high grade astrocytoma and metastasis).
  • Snail and E-cadherin showed less correlation in benign brain tumors.
  • Taken together, our results demonstrate that Hh signaling components, the expression and mutations of Snail and the expression of E-cadherin may play an important role in human brain tumorigenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Cadherins / genetics. Hedgehog Proteins / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878114.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


Advertisement
4. Chen Y, Zhang H, Xu A, Li N, Liu J, Liu C, Lv D, Wu S, Huang L, Yang S, He D, Xiao X: Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer; 2006 Oct;54(1):95-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To identify potential biomarkers related with lung cancer metastasis, conditional media (CM) proteins collected from a primary non-small cell lung cancer (NSCLC) cell line NCI-H226 and its brain metastatic subline H226Br were analyzed by one-dimensional electrophoresis (1-D PAGE) and matrix-assisted laser desorption/time of flight mass spectrometry (MALDI-TOF-MS).
  • Twelve biomarkers were identified, of which l-lactate dehydrogenase B (LDHB) chain was significantly up-regulated in the CM of H226Br cell and was further validated in 105 lung cancer, 93 non-lung cancer, 41 benign lung disease, as well as 65 healthy individuals sera using enzyme-linked immunosorbent assay (ELISA).
  • At the cutoff point 0.260 (OD value) on the receiver operating characteristic (ROC) curve, LDHB could comparatively discriminate lung cancer from benign lung disease and healthy control groups with sensitivity 81%, specificity 70% and total accuracy 76%.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / enzymology. L-Lactate Dehydrogenase / blood. Lung Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Electrophoresis, Polyacrylamide Gel. Enzyme-Linked Immunosorbent Assay. Female. Humans. Isoenzymes / blood. Male. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890323.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 1
  •  go-up   go-down


5. Sun FH, Piao YS, Wang W, Chen L, Wei LF, Yang H, Lu DH: [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases].
  • OBJECTIVE: To study the clinicopathologic features of brain tumors occurring in patients with medically intractable epilepsy.
  • METHODS: The clinical, radiologic and pathologic features of brain tumors occurring in 35 patients with intractable epilepsy encountered during the period from January, 2005 to April, 2008 in Xuanwu Hospital were retrospectively reviewed.
  • The histologic types of brain tumors included ganglioglioma (13/35, WHO grade I and 6/35, WHO grade II), dysembryoplastic neuroepithelial tumor (3/35, WHO grade I), pleomorphic xanthoastrocytoma (3/35, WHO grade II), diffuse astrocytoma (1/35, WHO grade II), oligoastrocytoma (1/35, WHO grade II), angiocentric glioma (1/35, WHO grade I) and meningioangiomatosis (1/35).
  • The 6 remaining cases showed features seen in between glioneuronal hamartoma and mixed neuronal-glial tumor.
  • Most of these tumors were located in the temporal lobe (27/35) and associated with focal cortical dysplasia.
  • CONCLUSIONS: Brain tumors in patients with medically intractable epilepsy are almost always benign and located in the temporal lobe.
  • Most of them represent mixed neuronal-glial tumors and some show transitional features in-between glioneuronal hamartoma and mixed neuronal-glial neoplasm.
  • The similar morphologic pattern and biological behavior of glioneuronal hamartoma and mixed neuronal-glial tumor may suggest a common pathogenetic mechanism.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Glioma / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / metabolism. Astrocytoma / complications. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / metabolism. Brain Diseases / pathology. Child. Child, Preschool. Female. Ganglioglioma / complications. Ganglioglioma / metabolism. Ganglioglioma / pathology. Hamartoma / complications. Hamartoma / metabolism. Hamartoma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Oligodendroglioma / complications. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Retrospective Studies. Temporal Lobe / pathology. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575848.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


6. Keshari KR, Kurhanewicz J, Jeffries RE, Wilson DM, Dewar BJ, Van Criekinge M, Zierhut M, Vigneron DB, Macdonald JM: Hyperpolarized (13)C spectroscopy and an NMR-compatible bioreactor system for the investigation of real-time cellular metabolism. Magn Reson Med; 2010 Feb;63(2):322-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although this preliminary study involved immortalized cells, this combination of technologies can be extended to the real-time metabolic exploration of primary benign and cancerous cells and tissues prior to and after therapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochimie. 2006 May;88(5):437-48 [16359766.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):187-96 [16432178.001]
  • [Cites] Biotechnol Bioeng. 2001 Sep 20;74(6):528-38 [11494221.001]
  • [Cites] Biotechnol Bioeng. 2002 Jan 5;77(1):83-90 [11745176.001]
  • [Cites] Biochem Pharmacol. 2002 Mar 1;63(5):843-51 [11911835.001]
  • [Cites] Magn Reson Med. 2002 Sep;48(3):430-9 [12210907.001]
  • [Cites] Anal Biochem. 2003 Jan 15;312(2):228-34 [12531210.001]
  • [Cites] Anal Biochem. 2003 Feb 1;313(1):145-54 [12576070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63 [12930897.001]
  • [Cites] J Theor Biol. 2007 Feb 7;244(3):500-10 [17049564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4359-64 [17360529.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1358-66 [17499003.001]
  • [Cites] Magn Reson Med. 2007 Jul;58(1):65-9 [17659629.001]
  • [Cites] Phytochemistry. 2007 Aug-Sep;68(16-18):2330-40 [17466349.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1382-7 [17965722.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1099-106 [17969006.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50 [18032601.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Chem Res Toxicol. 2008 Feb;21(2):408-20 [18095657.001]
  • [Cites] Nature. 2008 Mar 13;452(7184):230-3 [18337823.001]
  • [Cites] Bioprocess Biosyst Eng. 2008 Apr;31(3):227-39 [18074156.001]
  • [Cites] Magn Reson Med. 2008 Jul;60(1):33-40 [18581409.001]
  • [Cites] Brain. 2008 Aug;131(Pt 8):2209-19 [18669496.001]
  • [Cites] Magn Reson Med. 2008 Sep;60(3):510-6 [18727052.001]
  • [Cites] Cell. 2008 Sep 5;134(5):703-7 [18775299.001]
  • [Cites] Nat Biotechnol. 2008 Oct;26(10):1179-86 [18820684.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8607-15 [18922937.001]
  • [Cites] Mol Cancer. 2008;7:79 [18939998.001]
  • [Cites] J Cell Biochem. 2003 Oct 15;90(3):525-33 [14523987.001]
  • [Cites] Acta Physiol Scand. 1974 Sep;92(1):21-6 [4370414.001]
  • [Cites] NMR Biomed. 1990 Feb;3(1):23-6 [2390450.001]
  • [Cites] Biotechnology (N Y). 1990 Dec;8(12):1282-5 [1366962.001]
  • [Cites] Biochemistry. 1992 Aug 25;31(33):7488-93 [1510935.001]
  • [Cites] NMR Biomed. 1992 Jul-Aug;5(4):185-92 [1449954.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):244-8 [8429789.001]
  • [Cites] Am J Physiol. 1994 Jul;267(1 Pt 1):C195-203 [8048479.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2012-6 [7743493.001]
  • [Cites] Magn Reson Med. 1996 Feb;35(2):194-200 [8622583.001]
  • [Cites] J Lab Clin Med. 1996 Oct;128(4):408-16 [8833890.001]
  • [Cites] J Biol Chem. 1998 May 15;273(20):12187-94 [9575166.001]
  • [Cites] NMR Biomed. 1998 Apr;11(2):55-66 [9608589.001]
  • [Cites] Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52 [15386533.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Magn Reson Med. 2005 Jul;54(1):67-78 [15968647.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 12;333(4):1139-45 [15967408.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9369-76 [16230400.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10149-53 [16287997.001]
  • [Cites] Tissue Eng. 2006 Jul;12(7):2001-8 [16889528.001]
  • (PMID = 20099325.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NIBIB NIH HHS / EB / R01 EB007588; United States / NIBIB NIH HHS / EB / R21 EB007588; United States / NIGMS NIH HHS / GM / R21 GM075941-01; United States / NIGMS NIH HHS / GM / R21 GM075941-02; United States / NIGMS NIH HHS / GM / R21 GM075941-03; United States / NIGMS NIH HHS / GM / R21 GM075941; United States / NIBIB NIH HHS / EB / R01 EB007588-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS178870; NLM/ PMC2829258
  •  go-up   go-down


7. Mehrotra N, Shamji MF, Vassilyadi M, Ventureyra EC: Intracranial tumors in first year of life: the CHEO experience. Childs Nerv Syst; 2009 Dec;25(12):1563-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial tumors in first year of life: the CHEO experience.
  • INTRODUCTION: One seventh of pediatric brain tumors are diagnosed in the first year of life.
  • METHODS: A retrospective review was performed of brain tumor patients presenting to the Children's Hospital of Eastern Ontario (CHEO) through the last 34 years.
  • RESULTS: Eighteen cases of brain tumors in the first year of life were identified: 12 suptratentorial, eight with benign histology, and six infratentorial all with malignant histology.
  • Median age of presentation differed by lesion location (p = 0.05) and glial tumors were most common.
  • Raised intracranial pressure was more than twice as prevalent with posterior fossa lesions (p < 0.01) with equivalent likelihood of increasing head circumference (p = 0.74), whereas seizures were more frequent with supratentorial tumors (p = 0.04).
  • Among eight surviving infants, seven had supratentorial tumors, five survived to adulthood, and six are functionally independent.
  • CONCLUSIONS: Brain tumors in the first year of life represent 4.8% of patients treated at CHEO.
  • Mode of presentation, utilization of adjuvant therapy, and survival depend on tumor location and histology, with worse prognosis for infratentorial lesions.
  • [MeSH-major] Glioma / therapy. Infratentorial Neoplasms / therapy. Meningioma / therapy. Neuroectodermal Tumors, Primitive / therapy. Supratentorial Neoplasms / therapy. Teratoma / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropadiatrie. 1973 Jan;4(1):46-63 [4739778.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10):507-13 [9403197.001]
  • [Cites] Childs Nerv Syst. 2006 Feb;22(2):168-71 [15864706.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):295-303 [16807781.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5424-6 [16110000.001]
  • [Cites] Childs Nerv Syst. 1990 Mar;6(2):79-85 [2340533.001]
  • [Cites] Pediatr Neurol. 2002 Sep;27(3):230-3 [12393136.001]
  • [Cites] Childs Nerv Syst. 1994 Apr;10(3):172-5 [8044813.001]
  • [Cites] Childs Nerv Syst. 1989 Aug;5(4):230-3 [2790835.001]
  • [Cites] Childs Nerv Syst. 2006 Nov;22(11):1427-31 [16804715.001]
  • [Cites] Surg Neurol. 1984 Feb;21(2):165-70 [6322370.001]
  • [Cites] Childs Nerv Syst. 1991 Jun;7(3):150-3 [1878869.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1074-82 [17943961.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):311-4 [12732940.001]
  • [Cites] Childs Nerv Syst. 2006 Jul;22(7):729-33 [16673148.001]
  • [Cites] Arch Dis Child. 2008 Jul;93(7):582-9 [17634182.001]
  • [Cites] J Child Neurol. 2004 Jun;19(6):424-30 [15446390.001]
  • (PMID = 19551387.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Deb TB, Coticchia CM, Barndt R, Zuo H, Dickson RB, Johnson MD: Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation. Am J Physiol Cell Physiol; 2008 Aug;295(2):C365-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pnck (also known as CaM kinase Ibeta(2)) was previously shown to be differentially overexpressed in a subset of human primary breast cancers, compared with benign mammary epithelial tissue.

  • Genetic Alliance. consumer health - Pregnancy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 2001 Aug 17;911(1):1-11 [11489438.001]
  • [Cites] EMBO J. 2002 Feb 1;21(3):303-13 [11823423.001]
  • [Cites] Neuroscience. 2002;109(3):407-20 [11823055.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4812-21 [12101419.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35781-90 [12829707.001]
  • [Cites] Endocr Rev. 2003 Dec;24(6):719-36 [14671000.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13 [14967450.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2057-70 [15021893.001]
  • [Cites] Science. 1994 Aug 19;265(5175):1093-5 [8066447.001]
  • [Cites] Semin Cancer Biol. 1994 Aug;5(4):295-303 [7803766.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3679-86 [7641687.001]
  • [Cites] J Biol Chem. 1995 Sep 1;270(35):20242-5 [7657591.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 24;215(3):861-7 [7488053.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25332-5 [7592693.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1561-7 [7478580.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28654-9 [7499384.001]
  • [Cites] Mol Cell Biol. 1990 Oct;10(10):5521-4 [2398898.001]
  • [Cites] Science. 1991 Jun 7;252(5011):1427-30 [1646483.001]
  • [Cites] Pathobiology. 1991;59(5):329-34 [1716909.001]
  • [Cites] J Virol. 1992 Jan;66(1):197-203 [1727483.001]
  • [Cites] J Biol Chem. 1992 Jun 25;267(18):12742-52 [1377674.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13460-5 [1320021.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13466-71 [1320022.001]
  • [Cites] Annu Rev Biochem. 1992;61:559-601 [1323238.001]
  • [Cites] Tissue Cell. 1993;25(1):1-17 [8470090.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26512-21 [8253780.001]
  • [Cites] Breast Cancer Res Treat. 1994 Jan;29(1):127-38 [8018961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31 [8052651.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5617-22 [8621423.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):419-27 [9041461.001]
  • [Cites] Biochim Biophys Acta. 1997 Mar 7;1338(1):8-12 [9074610.001]
  • [Cites] Biochemistry. 1997 Oct 21;36(42):12823-7 [9335539.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32704-8 [9405489.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):49-55 [9495358.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16643-6 [9642214.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3663-74 [9851973.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):584-7 [9859994.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16168-73 [10347170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2328-33 [15695332.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):7038-48 [15590694.001]
  • [Cites] Mol Cell. 2005 May 27;18(5):601-7 [15916966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8525-30 [15937123.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35108-18 [16105844.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(2):389-401 [16382132.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1422-34 [16522318.001]
  • [Cites] Traffic. 2006 Jun;7(6):686-98 [16683917.001]
  • [Cites] FASEB J. 2006 Jun;20(8):1242-4 [16603604.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24064-72 [15150258.001]
  • [Cites] Mol Biol Cell. 2004 Aug;15(8):3591-604 [15194809.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38903-11 [15247222.001]
  • [Cites] Exp Cell Res. 2004 Nov 1;300(2):388-95 [15475003.001]
  • [Cites] Science. 1980 Jan 4;207(4426):19-27 [6243188.001]
  • [Cites] J Biol Chem. 1987 May 25;262(15):7273-81 [3108251.001]
  • [Cites] Cell. 1989 Apr 7;57(1):135-44 [2522818.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17275-80 [2507541.001]
  • [Cites] EMBO J. 2006 Sep 20;25(18):4195-206 [16932740.001]
  • [Cites] EMBO J. 2006 Dec 13;25(24):5683-92 [17139251.001]
  • [Cites] Mol Cell. 2007 Jan 12;25(1):151-9 [17218278.001]
  • [Cites] J Neurochem. 1999 Nov;73(5):2119-29 [10537072.001]
  • [Cites] Mol Cell. 1999 Dec;4(6):1029-40 [10635327.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genomics. 2000 Jan 15;63(2):279-88 [10673339.001]
  • [Cites] Curr Opin Neurobiol. 2000 Jun;10(3):375-80 [10851169.001]
  • [Cites] Brain Res. 2000 Jun 30;869(1-2):137-45 [10865068.001]
  • [Cites] Trends Cell Biol. 2000 Aug;10(8):322-8 [10884684.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21850-5 [10806200.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5571-7 [11034105.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Breast Cancer Res. 2000;2(3):176-83 [11250707.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:471-505 [11264466.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):193-9 [11318415.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27677-84 [11375397.001]
  • (PMID = 18562482.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 2P50CA58185; United States / NIA NIH HHS / AG / 2R01-AG-014963; United States / NCI NIH HHS / CA / NIH 4P30CA51008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Intracellular Signaling Peptides and Proteins; 0 / Leupeptins; 0 / Ligands; 0 / Macrolides; 0 / Phosphoproteins; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / RNA, Small Interfering; 0 / Recombinant Fusion Proteins; 0 / SHC1 protein, human; 0 / Shc Signaling Adaptor Proteins; 0 / Shc1 protein, mouse; 0 / Tyrphostins; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 170449-18-0 / tyrphostin AG 1478; 62229-50-9 / Epidermal Growth Factor; 88899-55-2 / bafilomycin A1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 1; EC 2.7.11.17 / PNCK protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC2518423
  •  go-up   go-down


9. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res; 2005 Aug 1;65(15):6726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
  • Malignant gliomas are deadly brain tumors characterized by diffuse invasion into the surrounding brain tissue.
  • Here we describe for the first time the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms, B/b(sia) and B/b(Deltag), which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies.
  • The glioma-specific expression of B/b(Deltag), its restricted membrane localization, and its expression in all high-grade gliomas tested to date suggest that it may play a significant role in glioma progression and make it an important new potential therapeutic target.
  • In addition, its absence from benign gliomas prompts its use as a diagnostic marker to distinguish primary brain tumors of similar histology but different pathologic course.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioma / metabolism. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01/NS35228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Brevican; 0 / Carrier Proteins; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


10. Pascual Castroviejo I, Pascual Pascual S, Velázquez Fragua R, Viaño J, Garcia Segura JM: [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients]. Neurologia; 2007 Dec;22(10):846-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients].
  • [Transliterated title] Tumores de tronco cerebral asociados con neurofibromatosis tipo 1. Presentación de 20 pacientes infantiles.
  • OBJECTIVE: To describe the clinical and imaging findings of 20 patients (12 women and 8 men) with brain stem tumors associated with neurofibromatosis type 1 (NF1).
  • Thirteen of the 20 patients (65 %) also had optic pathway tumor.
  • Brain stem tumor identification occurred at the same time as NF1 in the patients who were studied by MR at the time of the first consult.
  • RESULTS: Brain stem identification occurred at the same time as that of the NF1 in patients who were studied by MR from the beginning.
  • Diffuse or localized medullary enlargement was the most frequent MR imaging and appeared in 13 patients (65%), followed by the tumor that involved all brain stem (pontine and medullary areas) that appeared in 6 patients (30 %).
  • In the last group, one tumor showed extension through brain stem and medial cerebellar parts, another was located in the aqueduct and in the periaqueductal areas and showed slow progressive growth, and one third patient had a tumor with aggressive signs in the SMR study.
  • Another patient had an aggressive tumor that involved the left optic nerve, chiasm, mesencephalon and upper right pontine areas.
  • The histological study of the tumoral biopsic tissue of the two last patients showed astrocitoma degree 1 (benign tumor).
  • The two aggressive tumors were treated with radiotheraphy and chemotherapy and they are still alive 4 and 7 years respectively after treatment.
  • Only one of the 20 patients died, although it was due to a malignant chiasmatic tumor, that had been treated twenty years before, and not by the brain stem tumor.
  • CONCLUSIONS: In NF1, brain stem tumors are the most frequent tumors of the posterior fossa and the second most frequent of the central nervous system (CNS).
  • MR and SMR are necessary to a correct identification of the tumor in some patients.
  • Most of these tumors are benign.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Brain Stem. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neurofibromatosis 1 / complications


11. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


12. Schramm J, Aliashkevich AF: Surgery for temporal mediobasal tumors: experience based on a series of 235 patients. Neurosurgery; 2007 Feb;60(2):285-94; discussion 294-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for temporal mediobasal tumors: experience based on a series of 235 patients.
  • OBJECTIVE: To describe the clinical characteristics, diagnosis, various approaches, and outcomes in a retrospective review of a large series of temporomediobasal (TMB) tumors.
  • METHODS: Charts from 235 patients with TMB tumors were identified from the glioma and epilepsy surgery database and from the electronic operations log.
  • RESULTS: Two hundred and thirty-five patients with intra-axial TMB tumors (mean age, 35 yr) were collected during an 11-year period.
  • The largest tumor groups were astrocytomas (38.0%), gangliogliomas (29.8%), dysembryoplastic neuroepithelial tumor (11.1%), and glioblastomas (11.1%).
  • The most frequent tumor location was the mesial Type A tumor (45.1%), with this type also showing the highest proportion of benign (World Health Organization Grades I and II) histological features (91.3%).
  • Of all tumors, 76.2% were benign.
  • Larger tumor size was associated with higher frequency of malignant histopathological findings.
  • Thirty-eight patients with low-grade tumors had undergone surgery previously.
  • CONCLUSION: Small tumor size, magnetic resonance imaging, and microsurgery have made resection of mostly benign TMB tumors possible in a large number of patients.
  • This series supports the conclusion that these tumors can be operated on with a relative degree of safety for the patient, provided that the anatomy of the mesial temporal lobe and the variety of approaches are well known to the surgeon.
  • [MeSH-major] Brain Neoplasms / surgery. Neurosurgical Procedures. Temporal Lobe / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Neurosurgery. 2008 Jun;62(6 Suppl 3):1272-82 [18695547.001]
  • (PMID = 17290179.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y: The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol; 2009 Feb;131(2):264-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.
  • The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid neoplasia.
  • Vasculature is LMO2- in adult and fetal heart, brain of older adults, hepatic sinusoids, and hepatocellular carcinoma.
  • LMO2 is uniformly expressed in benign vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone.
  • Among nonvascular neoplasms, LMO2 reactivity is present in giant cell tumor of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141387.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / CA122105; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / P30 CA124435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS636776; NLM/ PMC4305438
  •  go-up   go-down


14. Monfared A, Agrawal S, Jackler RK: Cranial base approaches to inaccessible intracranial tumors. Curr Opin Neurol; 2007 Dec;20(6):726-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial base approaches to inaccessible intracranial tumors.
  • PURPOSE OF REVIEW: Craniotomy created through the base of the skull has improved exposure of many types of extraaxial tumors and thus enhanced both tumor control and preservation of neural function.
  • The increasingly documented efficacy of stereotactic radiation for certain tumor types (e.g. meningioma, schwannoma) has permitted nonoperative therapy for some individuals.
  • In large tumors, selective use of less-than-complete microsurgical resection is establishing an increasing role, at times combined with focused radiotherapy of the surgical remnant.
  • The role for transbasal craniotomy is well established in both benign tumors and vascular lesions, but has only limited applicability for high-grade malignant lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Craniotomy / methods. Neurosurgical Procedures / methods. Postoperative Complications / prevention & control. Skull Base / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992097.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


15. Gupta R, Suri V, Arora R, Sharma MC, Mishra S, Singh M, Sarkar C: Suprasellar ganglioglioma presenting with diabetes insipidus in a young boy: a rare clinical presentation. Childs Nerv Syst; 2010 Feb;26(2):255-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Gangliogliomas are rare tumors composed of an admixture of glial and neuronal components.
  • Due to this rarity, ganglioglioma is not considered in the differential diagnosis in a patient with diabetes insipidus.
  • Radiographic studies of the brain showed a solid and cystic mass in the suprasellar region effacing the third ventricle.
  • Intraoperatively, diffuse thickening of bilateral optic nerves and optic chiasma was noted and a diagnosis of optic glioma was considered.
  • This benign tumor should be kept in mind in patients with central diabetes insipidus and a suprasellar mass lesion.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Diabetes Insipidus / complications. Diabetes Insipidus / pathology. Ganglioglioma / complications. Ganglioglioma / pathology
  • [MeSH-minor] Brain / pathology. Brain / surgery. Child. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male


16. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


17. Broggi M, Darbar A, Teo C: The value of endoscopy in the total resection of pineocytomas. Neurosurgery; 2010 Sep;67(3 Suppl Operative):ons159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pineocytomas are rare pineal region tumors.
  • METHODS: A series of 15 patients (11 females, 4 males; mean age, 48 years) with histological diagnosis of pineocytoma were retrospectively reviewed.
  • The endoscope was used at various times throughout the case and consistently at the end to evaluate any possible residual tumor.
  • In 6 cases (40%), the endoscope was able to detect residual tumor located either behind the Vein of Galen or attached to the undersurface of the corpus callosum.
  • Residual tumor was then resected using a 30 degrees endoscope and dedicated angled endoscopic instruments.
  • With total removal of these histologically benign tumors patients may enjoy extended progression-free survival without adjuvant radiotherapy.
  • [MeSH-major] Brain Neoplasms / surgery. Endoscopy / methods. Neurosurgery / methods. Pineal Gland / surgery. Pinealoma / surgery. Ventriculostomy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679933.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Novak L, Molnar P, Lengyel Z, Tron L: Does increased 18FDG uptake reflect malignant transformation of a low-grade glioma? A diagnostic dilemma. Neurol India; 2005 Mar;53(1):112-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign gliomas of the brain show decreased uptake of 18F fluorodeoxyglucose (FDG) on positron emission tomography (PET).
  • In 1996, increased epileptic activity was accompanied by increased 18FDG uptake within the temporal part of the tumor.
  • Histological examination of the resected tumor showed no change in the pathology when compared with the first biopsy.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glioma / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805670.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Sarnat HB, Flores-Sarnat L: Embryology of the neural crest: its inductive role in the neurocutaneous syndromes. J Child Neurol; 2005 Aug;20(8):637-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the neurocutaneous syndromes, diverse features result from abnormal neural crest differentiation, providing a more encompassing embryologic basis for these disorders than the traditional view that these syndromes are somehow related to skin and brain because both are ectodermal derivatives.
  • Abnormal angiogenesis, areas of abnormal pigmentation that sometimes follow the lines of Blashko, nerve sheath proliferations, disorders of chromaffin tissue, lipomes and benign and malignant tumors are frequent features.
  • Many defective genes in neurocutaneous syndromes have an additional function as tumor suppressors.
  • The craniofacial abnormalities associated with many cerebral malformations and cutaneous lesions in some neurocutaneous syndromes emphasize an important inductive role of the neural tube in the development of non-neural tissues, mediated through neural crest.

  • MedlinePlus Health Information. consumer health - Craniofacial Abnormalities.
  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225807.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


20. Suehiro K, Pritzwald-Stegmann P, Lee KM, Teoh HH, Alison PM: Mediastinal and pulmonary metastases of malignant ossifying fibromyxoid tumor. Ann Thorac Surg; 2006 Jun;81(6):2289-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal and pulmonary metastases of malignant ossifying fibromyxoid tumor.
  • Ossifying fibromyxoid tumor is usually a benign tumor.
  • However some of these tumors with histologic and clinical evidence of malignancy have also been reported and little information is available regarding surgery for metastatic ossifying fibromyxoid tumor.
  • We present a case involving extensive excision of a huge metastatic ossifying fibromyxoid tumor occupying the upper mediastinum and upper half of the right hemithorax.
  • [MeSH-major] Fibroma, Ossifying / pathology. Lung Neoplasms / secondary. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Brain Neoplasms / complications. Brain Neoplasms / secondary. Diagnostic Errors. Fatal Outcome. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Lipoma / diagnosis. Neoplasm Invasiveness. Pericardium / pathology. Pericardium / surgery. Phrenic Nerve / pathology. Phrenic Nerve / surgery. Pneumonectomy. Radiotherapy, Adjuvant. Reoperation. Seizures / etiology. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Superior Vena Cava Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731174.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


21. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health


22. Yoshikawa G, Kawamoto S, Yakou K, Tsutsumi K: Massive intracranial hemorrhage associated with pleomorphic xanthoastrocytoma--case report. Neurol Med Chir (Tokyo); 2010;50(3):220-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had been treated with anticonvulsant medication under a diagnosis of left mesial temporal sclerosis based on magnetic resonance imaging findings.
  • Cerebral angiography on admission revealed occlusion of the P(2) segment of the left posterior cerebral artery (PCA) and extravasation of contrast medium during the procedure.
  • Presumably the bleeding was caused by the rupture of a pseudoaneurysm secondary to leptomeningeal involvement of this typically benign tumor.
  • [MeSH-major] Aneurysm, False / etiology. Aneurysm, Ruptured / etiology. Astrocytoma / complications. Brain Neoplasms / complications. Hematoma, Subdural, Intracranial / etiology. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Cerebral Angiography. Female. Humans. Middle Aged. Posterior Cerebral Artery. Severity of Illness Index. Temporal Lobe / blood supply. Temporal Lobe / pathology. Temporal Lobe / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339272.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Kenerson H, Dundon TA, Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res; 2005 Jan;57(1):67-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex (TSC) presents in the pediatric population with a constellation of benign tumors that affect the brain, heart, kidney, lung, and skin.
  • Consequently, TSC-related tumors exhibit uncontrolled activation of mTOR and its effectors.
  • Previous work has shown that a specific mTOR inhibitor, rapamycin, effectively down-regulated mTOR activity in renal tumors of Eker rats that carry a germline Tsc2 mutation.
  • Using this model, we investigated the effects of rapamycin on pituitary and renal tumors.
  • We observed that rats with pituitary tumors had significantly shorter survival than those without pituitary pathology.
  • Rapamycin also resulted in a significant decrease in the size of the Tsc2-related renal tumors.
  • In both types of pathology, tumor response was accompanied by down-regulation of ribosomal S6 kinase activity, reduction in cell size, and induction of apoptosis.
  • When rapamycin was given before onset of disease, subsequent development of macroscopic renal tumors was reduced, but no effect on the number of microscopic precursor lesions was found.
  • We conclude that rapamycin-sensitive mTOR activity was critical to tumor progression in the Eker rat model, but rapamycin is unlikely to eradicate all disease as a result of the development of drug resistance.
  • Our data also suggest the role of a rapamycin-insensitive pathway during tumor initiation.
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Disease Models, Animal. Disease Progression. Down-Regulation. Immunoblotting. Immunohistochemistry. Kidney / pathology. Mutation. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology. Protein Kinases / metabolism. Rats. Ribosomal Protein S6 Kinases / metabolism. TOR Serine-Threonine Kinases. Time Factors. Up-Regulation

  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15557109.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102662; United States / NCI NIH HHS / CA / CA61889
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, rat; EC 2.7.11.1 / Ribosomal Protein S6 Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


24. Chen H, Sun XF, Wu JS: [Clinicopathologic study of subependymal giant cell astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):656-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor often occurred in the lateral ventricles (16/18, 88.9%).
  • CONCLUSIONS: Subependymal giant cell astrocytoma is a benign brain tumor with distinctive histopathologic features.
  • The tumor typically affects children and young adults.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374208.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


25. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] Endocrine. 2001 Jun;15(1):29-38 [11572322.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6355-60 [16144946.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):320-6 [15355447.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1615-8 [9589665.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1048-54 [15754737.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:26-33 [15761229.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Aug;18(8):833-9 [9701344.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:1-11 [12566714.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Aug;23(4):307-14 [9292869.001]
  • [Cites] Expert Opin Pharmacother. 2004 May;5(5):1023-31 [15155105.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):662-9 [10603007.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] Neurosurg Clin N Am. 2003 Oct;14(4):571-91 [15024802.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7 [15135791.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):764-9 [9365064.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):663-9 [12447103.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7994-8004 [11050120.001]
  • [Cites] J Invest Surg. 2004 Sep-Oct;17(5):283-9 [15385261.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 [11836272.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


26. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - ADGRG6 - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2004 Dec 15;78(6):796-802 [15523643.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):179-92 [15691760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8633-8 [15932943.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] BMC Bioinformatics. 2006;7:35 [16430768.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] BMC Bioinformatics. 2006;7:84 [16504070.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] Development. 2006 Aug;133(15):2875-86 [16790476.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D116-21 [17178752.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Development. 2007 Sep;134(18):3271-81 [17699610.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):105-16 [18242511.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):658-69 [19041782.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1359-64 [9973626.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):117-23 [10612798.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41229-36 [11514554.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Apr 15;28(8):755-63 [12698117.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2357-65 [15014110.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):645-53 [1696266.001]
  • [Cites] Glia. 1996 Aug;17(4):327-38 [8856329.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [CommentIn] EMBO Mol Med. 2009 Jul;1(4):198-200 [20049721.001]
  • (PMID = 20049725.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / K01-NS049191; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human
  • [Other-IDs] NLM/ PMC3378132
  •  go-up   go-down


27. Sahu S, Lata I, Gupta D: Management of pregnant female with meningioma for craniotomy. J Neurosci Rural Pract; 2010 Jan;1(1):35-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial meningioma during pregnancy challenges the skill of obstetricians, neurosurgeons and neuroanesthesiologists in resection of the tumor and to secure delivery of the baby.
  • Urgent neurosurgical intervention is reserved for the management of malignancies, active hydrocephalus, and benign brain tumors associated with signs of impending herniation or progressive neurological deficit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2001 Feb;80(2):104-12 [11167203.001]
  • [Cites] Am J Obstet Gynecol. 2002 Sep;187(3):626-34 [12237639.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2127-32 [14751854.001]
  • [Cites] Arch Neurol. 1987 Feb;44(2):209-15 [3545159.001]
  • [Cites] J Neurosurg. 1991 Nov;75(5):731-9 [1919695.001]
  • [Cites] Am J Obstet Gynecol. 1994 Oct;171(4):1128-32 [7943085.001]
  • [Cites] J Reprod Med. 1995 Feb;40(2):154-6 [7738930.001]
  • [Cites] Can J Anaesth. 1999 Jan;46(1):61-5 [10078406.001]
  • [Cites] Clin Pharmacokinet. 2005;44(10):989-1008 [16176115.001]
  • [Cites] Pediatrics. 2006 May;117(5):1503-10 [16651303.001]
  • [Cites] Curr Opin Anaesthesiol. 2006 Oct;19(5):481-6 [16960478.001]
  • [Cites] Hypertension. 2007 Feb;49(2):334-40 [17200432.001]
  • [Cites] Anesth Analg. 2008 Jul;107(1):193-200 [18635488.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1150-7 [19408979.001]
  • (PMID = 21799618.001).
  • [ISSN] 0976-3155
  • [Journal-full-title] Journal of neurosciences in rural practice
  • [ISO-abbreviation] J Neurosci Rural Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3137832
  • [Keywords] NOTNLM ; Craniotomy / complications / meningioma / pregnancy
  •  go-up   go-down


28. Hernández Faraco A, Céspedes G, Trejo E: [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. Neurologia; 2009 May;24(4):235-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Expresión inmunohistoquímica del receptor de progesterona en relación con el grado histológico y riesgo de recidivas en meningiomas intracraneanos.
  • INTRODUCTION: Meningiomas are frequent primary neoplasms of the central nervous system, usually benign and susceptible to healing through surgery.
  • The histological grade of the WHO and the extension of the initial surgical resection are determining prognostic factors in these tumors.
  • Nevertheless, a recurrence rate close to 20 % in benign meningiomas completely diseccated arises the need of considering new prognostic factors.
  • RESULTS: Though the immunohistochemical labelling index (LI) of the PR decreased with the progression of the histological grade (means of 27.37 % for grade I, 17.89% for grade II, and 13.50% for grade III), such correlation was not statistically significant and the cut off estimated in 20% was not satisfactory to discriminate among benign meningiomas (grade I) and non benign (grades II-III) due to its poor sensitivity (56.10%) and positive predictive value (56.10 %).
  • The comparison of the LI of the PR among non recurrent meningiomas (36.35 %) and recurrent (22.10%) was neither statistically significant, but permitted to establish a useful cut off of 40% (LI >40% in 13/23 non recurrent tumors and <40% in 19/23 recurrent tumors) with a sensitivity of 82.61% and a positive predictive value of 65.52%.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Receptors, Progesterone / biosynthesis
  • [MeSH-minor] Adult. Biomarkers, Tumor. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603293.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone
  •  go-up   go-down


29. Hohenstein C, Herdtle S: Unexpected death from a colloid cyst. Int J Emerg Med; 2010;3(1):65-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Colloid cysts are usually benign brain tumors, which rarely cause acute neurological deterioration with sudden death due to an acute increase of intracranial pressure.
  • CONCLUSION: Subtle distinctions between symptoms due to intracranial hypertension, which typically cause headache and vomiting, and true gastroenteritis are discussed as well as the pathophysiology of neurogenic pulmonary edema and the origin of cerebral-triggered cardiac dysrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):392-5 [8869070.001]
  • [Cites] Ann Emerg Med. 1997 Apr;29(4):524-8 [9095015.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):367-70 [12140107.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):305-9 [16180045.001]
  • [Cites] J Clin Neurosci. 1995 Oct;2(4):307-11 [18638833.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Apr;51(4):447-55 [17378783.001]
  • [Cites] Physiol Res. 2008;57(4):499-506 [18052674.001]
  • [Cites] Am J Forensic Med Pathol. 2008 Jun;29(2):170-2 [18520488.001]
  • [Cites] Pediatr Cardiol. 2006 Mar-Apr;27(2):286-8 [16463127.001]
  • (PMID = 20414387.001).
  • [ISSN] 1865-1380
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2850975
  • [Keywords] NOTNLM ; Cardiopulmonary complication / Colloid cyst / Unexpected death
  •  go-up   go-down


30. Kim MS, Muratore C, Snelling L, Mandelbaum DE, McEachern R, Mangray S, Faizan M, Quintos JB: Ischemic stroke and rhabdomyolysis in a 15-year-old girl with paraganglioma due to an SDHB exon 6 (Q214X) mutation. J Pediatr Endocrinol Metab; 2009 Jun;22(6):565-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We report a 15-year-old girl with a recent diagnosis of type 2 diabetes mellitus who presented in malignant hypertensive crisis (BP 210/120 mm Hg).
  • RESULTS: Pathology showed a Zellballen pattern, negative tumor margins and benign para-aortic lymph nodes.
  • Mutation analysis of the succinate dehydrogenase type B (SDHB) gene revealed a heterozygous change of C to T at position 640 in exon 6 (Q214X) predicting an amino acid change to a stop codon.
  • [MeSH-major] Brain Ischemia / etiology. Germ-Line Mutation. Paraganglioma, Extra-Adrenal / genetics. Retroperitoneal Neoplasms / genetics. Rhabdomyolysis / etiology. Stroke / etiology. Succinate Dehydrogenase / genetics

  • Genetic Alliance. consumer health - Ischemic stroke.
  • Genetic Alliance. consumer health - Rhabdomyolysis.
  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694205.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


31. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


32. Lu Q, Dobbs LJ, Gregory CW, Lanford GW, Revelo MP, Shappell S, Chen YH: Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol; 2005 Oct;36(10):1037-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • delta-Catenin, or neural plakophilin-related armadillo protein, is a unique armadillo domain-containing protein in that it is neural-specific and primarily expressed in the brain.
  • The analyses of 90 human prostate cancer and 90 benign prostate tissue samples demonstrated that an estimated 85% of prostatic adenocarcinomas showed enhanced delta-catenin immunoreactivity. delta-Catenin expression increased with prognostically significant increased Gleason scores.
  • By analyzing the same tumor cell clusters using consecutive sections, we showed that an increased delta-catenin immunoreactivity was accompanied by the down-regulation and redistribution of E-cadherin and p120ctn, major cell junction proteins whose inactivation is frequently associated with cancer progression.
  • [MeSH-major] Armadillo Domain Proteins / metabolism. Cadherins / metabolism. Cell Adhesion Molecules / metabolism. Cytoskeletal Proteins / metabolism. Down-Regulation. Phosphoproteins / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Blotting, Western. Bone Marrow Cells / cytology. Catenins. Cell Line, Tumor. Cells, Cultured. Epithelial Cells / cytology. Epitopes. Fluorescent Antibody Technique. Green Fluorescent Proteins / metabolism. Humans. Immunohistochemistry. Male. Microarray Analysis. PC12 Cells. Precipitin Tests. Prognosis. Prostate / cytology. Radioimmunoassay. Rats. Stromal Cells / cytology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226102.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Armadillo Domain Proteins; 0 / Cadherins; 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Cytoskeletal Proteins; 0 / Epitopes; 0 / Phosphoproteins; 0 / delta catenin; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


33. Chen CM, Chen KH, Jung SM, Hsu HC, Wang CM: Central neurocytoma: 9 case series and review. Surg Neurol; 2008 Aug;70(2):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whether the high score of functional outcome was correlated with benign tumor course or 5-year survival rate remains uncertain.
  • We recommend regular follow-up for detecting tumor growth or recurrence, although central neurocytomas are always benign.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Neurocytoma / diagnosis. Neurocytoma / therapy
  • [MeSH-minor] Activities of Daily Living. Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cerebral Angiography. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / analysis. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Neurosurgical Procedures / methods. Radiotherapy / methods. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262625.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


34. Ramírez-Moreno JM, Ortega-Martínez M, Fernández-Gil MA, Bernal-García LM, Bejarano-Moguel V, Fernández-Portales I, Gómez-Baquero MJ, Cabezudo-Artero JM: [Isolated mesencephalic stroke related to a ruptured intracranial dermoid cyst]. Neurocirugia (Astur); 2009 Jun;20(3):272-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ictus isquémico mesencefálico aislado secundario a ruptura de quiste dermoide.
  • Dermoids cysts are embrionary benign lesions that comprise approximately 0.04-0.25% of all intracranial tumors.
  • Debut of this type of tumor as acute stroke is poorly reflected in literature.
  • [MeSH-major] Brain Neoplasms. Dermoid Cyst. Mesencephalon / pathology. Stroke

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575132.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


35. Garza R, Hudson RA 3rd, McMahan CA, Walter CA, Vogel KS: A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1. Mutat Res; 2007 Feb 3;615(1-2):98-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although most tumors that arise in humans with neurofibromatosis type 1 (NF1) are benign, these individuals are at increased risk for malignant peripheral nerve sheath tumors (MPNST).
  • To characterize additional mutations required for the development of MPNST from benign plexiform neurofibromas, we generated a mouse model for these tumors by combining targeted null mutations in Nf1 and p53, in cis.
  • CisNf1+/-; p53+/- mice spontaneously develop PNST, and these tumors exhibit loss-of-heterozygosity at both the Nf1 and p53 loci.
  • To quantitate spontaneous mutant frequencies (MF), we crossed the Big Blue mouse, which harbors a lacI transgene, to the cisNf1+/-; p53+/- mice, and isolated genomic DNA from both tumor and normal tissues in compound heterozygotes and wild-type siblings.
  • Many of the PNST exhibited increased mutant frequencies (MF=4.70) when compared to normal peripheral nerve and brain (MF=2.09); mutations occurred throughout the entire lacI gene, and included base substitutions, insertions, and deletions.
  • We conclude that a mild mutator phenotype arises in the tumors and tissues of cisNf1+/-; p53+/- mice, and propose that genomic instability influences NF1 tumor progression and disease severity.
  • [MeSH-minor] Animals. Brain / metabolism. Disease Models, Animal. Genes, p53. Humans. Liver / metabolism. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Mice, Transgenic. Nerve Sheath Neoplasms / genetics. Phenotype. Spleen / metabolism


41. Lönnrot K, Terho M, Kähärä V, Haapasalo H, Helén P: Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol; 2007 Sep;68(3):304-8; discussion 308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoplastic infantile ganglioglioma is a rare tumor occurring mainly in infants and young children.
  • Both radiological and histopathological appearances may resemble malignancy, although its clinical course is mainly benign.
  • METHODS: Altogether, 5 cases of DIG have been operated on in our hospital since the first diagnosis of DIG in Finland in 1993.
  • In 4 cases, there was a histopathologically verified single cystic tumor.
  • There were no recurrences in any of the patients after tumor resection.
  • For the first time, we describe EGFR and MYCN amplifications in tumors which are, respectively, of their mixed glial and neuronal origin.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / etiology. Ganglioglioma / diagnosis. Ganglioglioma / etiology
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Epilepsy / etiology. Follow-Up Studies. Humans. Male. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Oncogenes / physiology. Retrospective Studies. Treatment Outcome


42. Laxton AW, Shannon P, Nag S, Farb RI, Bernstein M: Rapid expansion of a previously asymptomatic subependymoma. Case report. J Neurosurg; 2005 Dec;103(6):1084-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One month after his initial presentation, he was admitted to the hospital with significant tumor expansion and clinical deterioration.
  • Histopathological analysis of this tumor showed central necrosis with associated edema in an otherwise typical and benign-appearing subependymoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Brain Edema / etiology. Cranial Fossa, Posterior. Craniotomy. Disease Progression. Headache / etiology. Humans. Male. Necrosis. Time Factors

  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381197.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Borgwardt L, Højgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C, Schmiegelow K: Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol; 2005 May 1;23(13):3030-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion.
  • PURPOSE Positron emission tomography (PET) has been used in grading of CNS tumors in adults, whereas studies of children have been limited.
  • PATIENTS AND METHODS Nineteen boys and 19 girls (median age, 8 years) with primary CNS tumors were studied prospectively by fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) PET with (n = 16) or without (n = 22) H(2)(15)O-PET before therapy.
  • The FDG uptake in tumors was semiquantitatively calculated by a region-of-interest-based tumor hotspot/brain index.
  • Eight tumors without histologic confirmation were classified as WHO grade 1 based on location, MRI, and clinical course (22 to 42 months).
  • Results Four grade 4 tumors had a mean index of 4.27 +/- 0.5, four grade 3 tumors had a mean index of 2.47 +/- 1.07, 10 grade 2 tumors had a mean index of 1.34 +/- 0.73, and eight of 12 grade 1 tumors had a mean index of -0.31 +/- 0.59.
  • For these 34 tumors, FDG uptake was positively correlated with malignancy grading (n = 34; r = 0.72; P < .01), as for the 26 histologically classified tumors (n = 26; r = 0.89; P < .01).
  • Digitally performed PET/MRI coregistration increased information on tumor characterization in 90% of cases.
  • CONCLUSION FDG PET of the brain with MRI coregistration can be used to obtain a more specific diagnosis with respect to malignancy grading.
  • Improved PET/MRI imaging of the benign hypermetabolic tumors is needed to optimize clinical use.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Prospective Studies. Regional Blood Flow. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860860.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Fayed-Miguel N, Morales-Ramos H, Modrego-Pardo PJ: [Magnetic resonance imaging with spectroscopy, perfusion and cerebral diffusion in the diagnosis of brain tumours]. Rev Neurol; 2006 Jun 16-30;42(12):735-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging with spectroscopy, perfusion and cerebral diffusion in the diagnosis of brain tumours].
  • [Transliterated title] Resonancia magnética con espectroscopia, perfusión y difusión cerebral en el diagnóstico de los tumores cerebrales.
  • AIM: We review three of the most important functional techniques in magnetic resonance imaging, it means spectroscopy, perfusion and diffusion; we do emphasize in its applications, particularly in the diagnostic and treatment of brain tumors.
  • DEVELOPMENT AND CONCLUSIONS: Choline containing compounds using contralateral creatine and choline for normalization or ipsilateral N-acetyl-aspartate appeared to correlate best with the degree of tumor infiltration, regardless o tumor histological grade.
  • Magnetic resonance spectroscopy imaging (MRSI) seems more accurate than conventional magnetic resonance imaging (MRI) in defining indistinct tumor boundaries and quantifying the degree of tumor infiltration.
  • Angiogenesis, and increased vascular permeability, are characteristic of cerebral neoplasms; these processes can be imaged using perfusion MRI.
  • Most commonly, tumor perfusion is measured using rapid gradient T2-weighted imaging during bolus injection of gadolinium dimeglumine gadopentetate.
  • Care has to be taken to avoid blood-brain barrier leakage affecting perfusion results.
  • Pharmacokinetic models are available for estimation of blood-brain permeability.
  • Cerebral blood volume increases with tumor grade, and maybe helpful in identifying tumor recurrence, and peri-tumoral edema, and distinguishing malignant from benign lesions.
  • [MeSH-major] Brain Neoplasms. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Biomarkers, Tumor / chemistry. Biomarkers, Tumor / metabolism. Blood-Brain Barrier / physiology. Brain Chemistry. Cerebrovascular Circulation. Choline / chemistry. Choline / metabolism. Contrast Media / metabolism. Image Processing, Computer-Assisted. Neoplasm Staging. Permeability. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775800.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; N91BDP6H0X / Choline
  •  go-up   go-down


45. Carlson ML, Babovic-Vuksanovic D, Messiaen L, Scheithauer BW, Neff BA, Link MJ: Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg; 2010 Jan;112(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas.
  • The gene responsible for the development of NF2 acts as a tumor suppressor gene.
  • Stereotactic radiotherapy (SRT) or single-fraction stereotactic radiosurgery has been increasingly used in the past decades to treat benign tumors in patients with NF2.
  • These radiotherapy methods are less invasive and can be potentially used to treat multiple tumors in a single session.
  • Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2.
  • Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
  • [MeSH-major] Brain Stem Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neurofibromatosis 2 / surgery. Radiosurgery / adverse effects. Rhabdomyosarcoma / etiology
  • [MeSH-minor] Adult. Brain Neoplasms / etiology. Brain Neoplasms / surgery. Brain Stem / pathology. Brain Stem / radiation effects. Brain Stem / surgery. Ear Neoplasms / etiology. Ear Neoplasms / surgery. Fatal Outcome. Female. Humans. Neurilemmoma / etiology. Neurilemmoma / surgery. Vestibular Diseases / etiology. Vestibular Diseases / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):209. Scheithauer, Bernd B [corrected to Scheithauer, Bernd W]
  • (PMID = 19575577.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Harada M, Ishihara Y, Itoh K, Yamanaka R: Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep; 2007 Mar;17(3):629-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we searched for new target candidates in specific immunotherapy for malignant glioma by utilizing cDNA microarray technology to compare gene expressions in malignant glioma tissues to those in benign glioma and a panel of normal tissues.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Brain Neoplasms / immunology. Glioma / immunology. HLA-A Antigens / immunology. Kinesin / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Cancer Vaccines. Cell Line, Tumor. Gene Expression. Gene Expression Profiling. HLA-A24 Antigen. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunotherapy / methods. Oligonucleotide Array Sequence Analysis. Peptides / immunology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273744.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A24 Antigen; 0 / Immunoglobulin G; 0 / Peptides; 0 / RNA, Messenger; EC 3.6.1.- / Kinesin
  •  go-up   go-down


47. Feng Y, Yang ZG, Chen T, Wang Q, Deng W: Giant plexiform neurofibroma with hemorrhage in cranio-maxillofacial region as depicted on CT and MRI. Eur J Med Res; 2010 Feb 26;15(2):84-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plexiform neurofibroma (PN) is a rare benign tumor and a special subtype of neurofibromatosis type 1 (NF1).
  • [MeSH-major] Hemorrhage / diagnosis. Maxillary Neoplasms / diagnosis. Neurofibroma, Plexiform / diagnosis

  • Genetic Alliance. consumer health - Neurofibroma.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 2000 May 15;92(2):132-5 [10797438.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jan;176(1):75-82 [11133542.001]
  • [Cites] AJR Am J Roentgenol. 2001 Feb;176(2):493-5 [11159102.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):601-12 [11353109.001]
  • [Cites] Can J Gastroenterol. 2001 Dec;15(12):835-7 [11773950.001]
  • [Cites] Pediatrics. 2008 Mar;121(3):633-42 [18310216.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):79-82 [16029330.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):126-8 [16418370.001]
  • [Cites] Brain Dev. 2006 Jun;28(5):275-80 [16481142.001]
  • [Cites] Head Neck. 2002 Feb;24(2):207-11 [11891951.001]
  • (PMID = 20452890.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3352051
  •  go-up   go-down


48. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.
  • Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B.
  • Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


49. Adam C, Polivka M, Carpentier A, George B, Gray F: Papillary glioneuronal tumor: not always a benign tumor? Clin Neuropathol; 2007 May-Jun;26(3):119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary glioneuronal tumor: not always a benign tumor?
  • Papillary glioneuronal tumor (PGNT) is a variant of ganglioglioma, characterized by a pseudopapillary structure with a single pseudostratified layer of small, cuboidal, GFAP-positive cells around hyalinized blood vessels.
  • To date, less than 30 cases have been described with a usually benign course.
  • We report two additional cases: a clinically, radiologically and histopathologically typical tumor in a 38-year-old man and an atypical tumor with histopathological features of anaplasia in a 74-year-old woman.
  • The latter tumor showed the classical pseudopapillary pattern with ganglioid cells and some astrocytes between the papillae, but also had changes suggestive of anaplasia including necrosis, capillary endothelial proliferation, mitoses, dedifferentiation with loss of GFAP expression of the cuboidal cells and increased Ki-67 labeling of over 10%.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157003.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Bookland MJ, Bagley CA, Schwarz J, Burger PC, Brem H: Intracavernous trigeminal ganglion amyloidoma: case report. Neurosurgery; 2007 Mar;60(3):E574; discussion E574
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To the authors' knowledge, there have been 52 documented cases of primary amyloid tumors of the central nervous system and closely associated structures.
  • Brain magnetic resonance imaging was acquired, demonstrating abnormal contrast enhancement and enlargement of the right trigeminal ganglion.
  • With the site of the tumor within the cavernous sinus verified by pathology, the remainder of the tumor was removed.
  • A final pathological review of the resected tumor confirmed a diagnosis of amyloidoma of the trigeminal ganglion.
  • Even in the absence of systemic signs of amyloidosis, this benign protein deposition disease should be considered in the differential for atypical dysesthesias of the trigeminal dermatomes.

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327767.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas.
  • Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays.
  • The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • Finally, we demonstrated that PASCs are pituitary tumour-initiating cells in serial transplantation animal experiments.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.
  • The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


52. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY: A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg; 2010 May;112(5):925-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
  • The goal of this study was to identify clinical characteristics associated with the recurrence of benign meningiomas and their acceleration to atypical and malignant histological types.
  • Consequently, patients with Grade I non-skull base cranial meningiomas had better 5-year recurrence-free survival (69%) than patients with Grade I skull base meningiomas (56%) or Grade II or III tumors at any site (50%; p = 0.005).
  • Unexpectedly, patients with non-skull base tumors who experienced a recurrence (8 of 22 [36%]) were more likely than patients with skull base tumors (1 of 19 [5%]) to have a higher grade tumor at recurrence (p = 0.024).
  • Furthermore, the median MIB-1 labeling index of Grade I non-skull base cranial meningiomas (2.60%) was significantly higher than that of Grade I skull base tumors (1.35%; p = 0.016).
  • CONCLUSIONS: Cranial meningiomas that occur outside of the skull base are more likely to have a higher MIB-1 labeling index and recur with a higher grade than those within the skull base, suggesting that non-skull base cranial tumors may have a more aggressive biology than skull base tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local. Skull Base Neoplasms / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799498.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pui MH, Wang Y: Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children. Clin Imaging; 2005 May-Jun;29(3):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children.
  • The purpose of this study was to determine the efficacy of diffusion-weighted imaging (DWI) and magnetization transfer imaging (MTI) in the differential diagnosis of brain infarct, infection, hamartoma, and tumor in 106 children.
  • There was an inverse relationship between ADC and MTR in subacute/chronic infarct, infection, hamartoma, arachnoid cyst, and tumor relative to normal brain parenchyma.
  • DWI and MTI had a complementary role in the differential diagnosis of acute infarct from infection with lower MTR, from hamartoma with higher ADC, and from low-grade gliomas and benign tumors that had higher ADCs and lower MTRs.
  • ADCs increased and MTRs decreased with the duration of infarct and lower tumor grade.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Central Nervous System Infections / diagnosis. Cerebral Infarction / diagnosis. Diffusion Magnetic Resonance Imaging. Image Processing, Computer-Assisted
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855060.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Lee DK, Cho KT, Im SH, Hong SK: Pleomorphic xanthoastrocytoma with an intracystic hemorrhage : a case report and literature review. J Korean Neurosurg Soc; 2007 Nov;42(5):410-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) has been considered as a low grade tumor of adolescents and young adults.
  • Although this tumor often shows cystic component, the hemorrhage within the cyst is extremely rare.
  • After gross total resection of the tumor, the patient was fully recovered from neurological deficit.
  • It is suggested that this typically benign tumor could be presented with hemorrhage, causing a rapid neurological deterioration.
  • Prompt surgical intervention, especially total removal of the tumor can provide an excellent functional recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):269-74 [8293186.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Nov-Dec;14(6):1397-404 [8279337.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):353-5 [1513442.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):1079-82; discussion 1082 [12234421.001]
  • [Cites] Br J Radiol. 2001 Mar;74(879):270-2 [11338106.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):169-71 [15690134.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):154-6 [8770268.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):564-9 [8113873.001]
  • (PMID = 19096580.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588191
  • [Keywords] NOTNLM ; Cyst / Hemorrhage / Mural nodule / Pleomorphic xanthoastrocytoma (PXA)
  •  go-up   go-down


56. Ammoury RF, Heptulla RA, Tatevian N, Elenberg E: Laparoscopic adrenalectomy of an adrenal adenoma with myelolipoma relieves severe hypertension in a 16-year-old patient. Pediatr Nephrol; 2006 Mar;21(3):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the tumor is usually asymptomatic, sometimes it may result in serious manifestations.
  • The laboratory work-up was inconclusive of the nature of the tumor.
  • Magnetic resonance imaging (MRI) of the brain and meta-iodobenzylguanidine (MIBG) scanning were normal.
  • After tumor resection the hypertension resolved, and within 1 month the patient was off medications.
  • This is a case in which an adrenal adenoma with myelolipoma, a benign and usually asymptomatic tumor, presented as severe hypertension resolving with surgical resection of the tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy. Adrenocortical Adenoma / surgery. Hypertension / etiology. Laparoscopy. Myelolipoma / surgery. Neoplasms, Multiple Primary / surgery


57. Al-Otaibi M, Lach B, Al Shail E: December 2004: one-year-old girl with aggressive skull tumor. Brain Pathol; 2005 Apr;15(2):171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] December 2004: one-year-old girl with aggressive skull tumor.
  • December 2004. Twelve-month old girl presented with recurrent subcutaneous lesion in the left parietal region, one year after excision of a "benign" tumor.
  • An MRI demonstrated left temporo-parietal skull tumor infiltrating the soft tissue, surrounding craniotomy flap, and extending to the brain parenchyma.
  • Biopsy revealed biphasic neoplasm displaying nests of poorly differentiated neuroblastic cells positive for synaptophysin and pigmented cuboidal epithelioid cell positive for keratins, epithelial membrane antigen and MHB-45.
  • Interestingly, cell with the neuroblastic immunophenotype displayed 80% nuclear MIB-1 reactivity indicating that the aggressiveness of the neoplasm was confined mostly to this pattern of differentiation.
  • The overall histological features are consistent with a rare malignant variant of a melanotic neuroectodermal tumor of infancy.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neuroectodermal Tumor, Melanotic / pathology. Parietal Bone / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / secondary. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Soft Tissue Neoplasms / secondary. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912891.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


58. Naimi-Akbar C, Ritter M, Demel S, El-Nour H, Hedblad MA, Azmitia EC, Nordlind K: Different serotonergic expression in nevomelanocytic tumors. Cancers (Basel); 2010;2(2):1166-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different serotonergic expression in nevomelanocytic tumors.
  • The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression.
  • Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors.
  • For this purpose, paraffin-embedded biopsies of superficial spreading malignant melanoma (SSM), dysplastic compound nevi (DN) and benign compound nevi (BCN) were characterized with regard to their expression of 5-HT, the 5-HT1A and 5-HT2A receptors, and the serotonin transporter protein (SERT), by immunohistochemical analysis.
  • Melanocytes in the region surrounding the tumor were found to express both the 5-HT1A and 5-HT2A receptors.
  • Tumor cells that immunostained positively for the different serotonergic markers were observed in the suprabasal epidermis of DN tissue and, to an even greater extent, in the case of SSM.
  • As the degree of atypia increased, the intensity of tumor cell staining in the dermis for 5-HT1AR and SERT declined.
  • Round-to-dendritic cells that expressed both SERT and 5-HT1AR were seen to infiltrate into the dermal region of the tumor, this infiltration being more evident in the case of DN and SSM.
  • Thus, alterations in serotonergic system may be involved in nevomelanocytic tumors and mast cells may play an important role in this connection.

  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281111.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3835124
  •  go-up   go-down


59. Buchanich JM, Youk AO, Marsh GM, Kennedy KJ, Esmen NA, Lacey SE, Hancock R, Cunningham MA, Lieberman FS, Fleissner ML: Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. Ann Epidemiol; 2010 Oct;20(10):759-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare ascertainment of central nervous system (CNS) neoplasms with the use of mortality and incidence data as part of an occupational epidemiology study.
  • Compared with state cancer registries, death certificates missed 38% of the malignant, more than six times the benign and nearly 1.5 times the unspecified CNS cases.
  • The positive predictive value of death certificates, with cancer registry as gold standard, was 6% for unspecified, 35% for benign, and 86% for malignant histologies.
  • CONCLUSIONS: Death certificates seriously underascertained benign and unspecified CNS tumors; analyses determined with mortality data would not accurately capture the true extent of disease among the cohort.
  • Most state cancer registries have only collected nonmalignant CNS tumor information since 2004, which currently limits the usefulness of state cancer registries as a source of nonmalignant CNS tumor identification.
  • [MeSH-major] Brain Neoplasms / epidemiology. Cranial Nerve Neoplasms / epidemiology. Death Certificates. Occupational Exposure. Registries / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20816315.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Sanchez-Mejia RO, Pham DN, Prados M, Tihan T, Cha S, El-Sayed I, McDermott MW: Management of a sporadic malignant subfrontal peripheral nerve sheath tumor. J Neurooncol; 2006 Jan;76(2):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of a sporadic malignant subfrontal peripheral nerve sheath tumor.
  • Malignant subfrontal (olfactory) peripheral nerve sheath tumors (MPNSTs) are exceedingly rare.
  • Brain-imaging studies revealed a large left subfrontal mass with extension into the frontal and ethmoid sinuses and the nasal cavity.
  • Subfrontal PNSTs are extremely rare and usually benign.
  • The specific cell and nerve of origin for these tumors remains unknown.
  • Our case shows that these rare lesions can present as a malignant variant and thus require aggressive surgical and postoperative management to provide long-term tumor control.
  • [MeSH-major] Brain Neoplasms / pathology. Nerve Sheath Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2002 Apr;12(4):742-4 [11960220.001]
  • [Cites] Singapore Med J. 2001 Jun;42(6):275-7 [11547967.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(5):401-5 [8116230.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Jan;124(1):109,111-2 [9440794.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Neurologia. 2000 Nov;15(9):404-5 [11195149.001]
  • [Cites] Clin Neurol Neurosurg. 1999 Mar;101(1):26-8 [10350200.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Apr;44(4):191-4 [15185758.001]
  • [Cites] Zentralbl Neurochir. 1968;29(4):217-22 [5731427.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):194-7 [8971843.001]
  • [Cites] Neurol India. 2004 Jun;52(2):261-2 [15269489.001]
  • [Cites] Clin Neurol Neurosurg. 1995 May;97(2):187-91 [7656497.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(6):671-2 [10929737.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 16132491.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Lozada D, Brau RH: Stereotactic radiosurgery for intracranial tumors: Puerto Rico experience. P R Health Sci J; 2010 Sep;29(3):286-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for intracranial tumors: Puerto Rico experience.
  • Since its introduction, stereotactic radiosurgery has evolved from an investigational concept into a recognized neurosurgical procedure for the management of a wide variety of brain disorders.
  • The goal of this research was to describe the experience in Puerto Rico using this technology and review the efficacy, safety, and role of radiosurgery in the treatment of the most common intracranial tumors treated today.
  • Patients treated from 1999-2009 at Clinicas Las Americas were reviewed and medical literature databases were searched for articles pertaining to stereotactic radiosurgery performed in these intracranial tumor pathologies: meningiomas, gliomas, cerebral metastasis, vestibular schwannomas and pituitary adenomas.
  • Each study was examined to determine the radiosurgical parameters, duration of follow-up review, tumor growth control rate and complications.
  • Radiosurgery in benign tumors resulted in the control of tumor size in 90% of treated patients.
  • Unfortunately radiosurgery for malignant tumors is not curative, but has been effective in improving survival and quality of life.
  • [MeSH-major] Brain Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799517.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Puerto Rico
  • [Number-of-references] 50
  •  go-up   go-down


62. Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA: Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol; 2006 Nov;126(5):798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated 123 formalin-fixed, paraffin-embedded samples, including neuroendocrine tumors, adult brain, mesonephric tissues, and from various other sites.
  • Our study describes for the first time distribution of Pax-5 in adult brain tissue, including periaqueductal gray matter of the midbrain, area postrema of the medulla oblongata, and occasional cells of the spinal trigeminal nucleus (caudal nucleus).
  • We confirm that Pax-5 is expressed regularly in poorly differentiated neuroendocrine tumors but never in well-differentiated classic carcinoid tumors.
  • Pax-5 expression also was found readily in benign and malignant mesonephric tissues and focally in müllerian duct-derived tissues and tumors.
  • Together, these results are important for correct interpretation of results in immunophenotyping of undifferentiated tumors, for diagnosis of mesonephric carcinoma, and, potentially, for correct classification of neuroendocrine tumors in small biopsy samples.
  • [MeSH-major] B-Cell-Specific Activator Protein / biosynthesis. Carcinoma, Small Cell / metabolism. Neuroendocrine Tumors / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Cell Line, Tumor. Female. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050077.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human
  •  go-up   go-down


63. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO: Reduced apoptosis rates in human schwannomas. Brain Pathol; 2005 Jan;15(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas, tumors originating from Schwann cells, represent a frequent neurological tumor and can occur both in a genetic disorder called neurofibromatosis type 2 (NF2) and sporadically.
  • In both cases the genetic background is identical as all schwannomas are caused by biallelic mutations in the tumor suppressor gene NF2 coding for merlin.
  • Here, we report in vivo and in vitro evidence that the basal apoptosis rate of primary human schwannoma cells is reduced in comparison to that of normal Schwann cells, supporting the idea that in this benign tumor type, apoptosis has a role in tumorigenesis.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779232.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


64. Benatiya AI, Bouayed MA, Touiza E, Daoudi K, Mernissi FZ, Tahri H: [Bourneville's tuberous sclerosis. A case report]. J Fr Ophtalmol; 2005 Dec;28(10):e11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La sclérose tubéreuse de Bourneville. A propos d'un cas.
  • INTRODUCTION: Bourneville's tuberous sclerosis (BTS) is an autosomal dominant phakomatosis characterized by the development of a benign hamartoma-like tumor, which is usually located in the skin, kidney, heart, brain, and eyes.
  • We present here a case of a retinal BTS of late diagnosis.
  • The chest X-ray, renal scan, heart scan and a CT scan of the brain failed to show any other localizations of the disease.
  • They are often an incidental diagnosis and evolve slowly.
  • [MeSH-major] Retinal Neoplasms / diagnosis. Tuberous Sclerosis / diagnosis

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395191.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


65. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • CONCLUSIONS: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


66. Waltereit R, Welzl H, Dichgans J, Lipp HP, Schmidt WJ, Weller M: Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J Neurochem; 2006 Jan;96(2):407-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TSC starts in early childhood and is characterized by cerebral hamartomas (benign tumours), severe epilepsy and cognitive deficits such as mental retardation and autism.
  • The hamartomas are characterized by loss of the remaining wild-type TSC allele, and clinical data implicate cerebral hamartomas in the generation of epileptic seizures, which may play a significant role in the development of mental retardation.
  • We therefore hypothesized that the heterozygous mutation itself, besides cerebral hamartomas, contributes to the pathogenesis of cognitive deficits and possibly also epilepsy.
  • Here, we show that young adult TSC2+/- rats, which are virtually free of cerebral hamartomas, exhibit enhanced episodic-like memory and enhanced responses to chemically-induced kindling.
  • [MeSH-major] Epilepsy / etiology. Kindling, Neurologic. Memory, Short-Term. Mutation. Tuberous Sclerosis / genetics. Tuberous Sclerosis / psychology. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epilepsy Curr. 2006 Nov-Dec;6(6):210-2 [17260062.001]
  • (PMID = 16300636.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1
  •  go-up   go-down


67. Fisher MJ: The Use of PET in the Evaluation of Tumors in Children with Neurofibromatosis Type 1. PET Clin; 2008 Oct;3(4):531-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Use of PET in the Evaluation of Tumors in Children with Neurofibromatosis Type 1.
  • Neurofibromatosis type 1 (NF1) is one of the most common tumor predisposition disorders.
  • The role of PET for distinguishing tumor from non-malignant processes, detecting and grading tumors, evaluating tumor margins, predicting prognosis, directing biopsy, planning treatment, and evaluating response to therapy has been established for a wide variety of benign and malignant tumors.
  • Children with NF1 are particularly at risk for the development of tumors of the peripheral and central nervous system, such as neurofibromas, malignant peripheral nerve sheath tumors, and low-grade astrocytomas of the optic pathway and other brain regions.
  • This article reviews the role of PET in the management of these NF1-associated tumors of childhood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Inc. All rights reserved.
  • (PMID = 27156818.001).
  • [ISSN] 1556-8598
  • [Journal-full-title] PET clinics
  • [ISO-abbreviation] PET Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Low-grade glioma / Malignant peripheral nerve sheath tumor / Neurofibromatosis type 1 / Optic pathway glioma / Plexiform neurofibroma / Positron emission tomography
  •  go-up   go-down


68. Saraswathy A, Jayasree RS, Baiju KV, Gupta AK, Pillai VP: Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy. Photomed Laser Surg; 2009 Jun;27(3):425-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum wavelength for the differentiation of brain tumor tissue using autofluorescence spectroscopy.
  • OBJECTIVE: The role of autofluorescence spectroscopy in the detection and staging of benign and malignant brain tumors is being investigated in this study, with an additional aim of determining an optimum excitation wavelength for the spectroscopic identification of brain tumors.
  • MATERIALS AND METHODS: The present study involves in-vitro autofluorescence monitoring of different human brain tumor samples to assess their spectroscopic properties.
  • The autofluorescence measurement at four different excitation wavelengths 320, 370, 410, and 470 nm, were carried out for five different brain tumor types: glioma, astrocytoma, meningioma, pituitary adenoma, and schwannoma.
  • RESULTS: The fluorescence spectra of tumor tissues showed significant differences, both in intensity and in spectral profile, from those of adjacent normal brain tissues at all four excitation wavelengths.
  • Of the four excitation wavelengths being considered, 470 nm appeared to be the optimal wavelength for detecting tissue fluorescence of brain tumor tissues.
  • CONCLUSIONS: In conclusion, the spectroscopic luminescence measurements carried out in this study revealed significant differences between tumor tissue and adjacent normal tissue of human brains for all the tumor types tested, except for pituitary adenoma.
  • From the results of this study we conclude that excitation wavelengths ranging from 410-470 nm are most suitable for the detection of brain tumor tissue.
  • [MeSH-major] Brain Neoplasms / pathology. Spectrometry, Fluorescence / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Astrocytoma / pathology. Child. Child, Preschool. Discriminant Analysis. Female. Glioma / pathology. Humans. Male. Meningioma / pathology. Middle Aged. Neoplasm Staging. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025404.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, Reeder JE: Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol; 2005 Jun;166(6):1807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After an initial response in most patients, tumors invariably progress to an androgen-independent state.
  • Using immunohistochemistry, we show that interleukin-8 was expressed by the neuroendocrine tumor cells in human prostate cancer tissue.
  • Expression of the interleukin-8 receptor CXCR1 was negative or low in benign prostatic tissue and was frequently increased in malignant cells of high-grade prostatic intraepithelial neoplasia and prostate cancer; however, CXCR1 was not detected in the neuroendocrine tumor cells, suggesting a paracrine mechanism by which interleukin-8 produced by neuroendocrine tumor cells stimulates androgen-independent proliferation of prostate cancer.
  • Neuroendocrine tumor cells expressed another type of interleukin-8 receptor, CXCR2, suggesting an autocrine mechanism by which interleukin-8 regulates the differentiation or function of the neuroendocrine cells.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Interleukin-8 / biosynthesis. Prostatic Neoplasms / pathology. Receptors, Interleukin-8A / biosynthesis. Receptors, Interleukin-8B / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1991 Sep 13;253(5025):1280-3 [1891716.001]
  • [Cites] Science. 1991 Sep 13;253(5025):1278-80 [1840701.001]
  • [Cites] Chem Immunol. 1992;51:236-65 [1567543.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):254-68 [1350941.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2358-66 [1382099.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1798-801 [1281554.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):1338-42 [8419336.001]
  • [Cites] Brain Res. 1993 Jan 8;600(1):49-55 [8422590.001]
  • [Cites] J Urol. 1993 May;149(5):1209-13 [8097794.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):285-92 [8363581.001]
  • [Cites] FEBS Lett. 1994 Mar 21;341(2-3):187-92 [8137938.001]
  • [Cites] Verh Dtsch Ges Pathol. 1993;77:107-10 [7511265.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jun;118(6):616-8 [8204007.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5474-8 [7522959.001]
  • [Cites] Eur Urol. 1995;27 Suppl 2:45-7 [7750532.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Prostate Suppl. 1996;6:3-8 [8630226.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):910-6 [8826857.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2882-90 [9058825.001]
  • [Cites] Curr Biol. 1997 Feb 1;7(2):112-21 [9024623.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):450-9 [9092797.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):164-70 [9485196.001]
  • [Cites] Urology. 1998 Apr;51(4):585-9 [9586611.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7379-84 [9636157.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4640-5 [9788616.001]
  • [Cites] Urology. 1999 Jan;53(1):139-47 [9886603.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8316-21 [10075738.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] Prostate. 1999 Oct 1;41(2):78-88 [10477904.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] Prostate. 2000 Mar 1;42(4):274-9 [10679756.001]
  • [Cites] Endocrine. 1999 Oct;11(2):195-202 [10709768.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2104-19 [10815938.001]
  • [Cites] Pathol Res Pract. 2000;196(5):277-84 [10834383.001]
  • [Cites] J Urol. 2000 Oct;164(4):1420-5 [10992426.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):313-35 [11544102.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9 [12231070.001]
  • [Cites] Trends Pharmacol Sci. 2002 Oct;23(10):459-67 [12368070.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6039-44 [12414626.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 2):S36-40 [14713751.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2197-205 [14767470.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):411 [15453805.001]
  • [Cites] Pathol Res Pract. 1987 Jun;182(3):298-307 [2442732.001]
  • [Cites] Prostate. 1989;14(2):103-15 [2710689.001]
  • [Cites] Pathol Res Pract. 1989 Sep;185(3):373-80 [2813190.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Dec 14;173(2):534-40 [2260966.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):287-96 [1313390.001]
  • (PMID = 15920165.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  • [Other-IDs] NLM/ PMC1602414
  •  go-up   go-down


70. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • BACKGROUND: Tumor-to-tumor metastasis is a rare, but well-reported, curiosity in which one type of primary neoplasm metastasizes to another primary tumor type within the same person.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • In examples where the donor tumor type is a hematopoietic neoplasm, significant edema can be produced by the tumor-to-tumor metastasis.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kim DW, Jung SA, Kim CG, Park SA: The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med; 2010 Jun;35(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors.
  • PURPOSE: Several studies have explored the usefulness of dual time point F-18 FDG positron emission tomography imaging (DTPI) in improving detection of brain metastases and tumors outside the brain, distinguishing malignant from benign.
  • In the same manner, DTPI may show better performance to grade of brain tumors.
  • METHODS: Twenty-two lesions of 18 consecutive patients with primary or metastatic brain tumor were included prospectively.
  • RESULTS: SUVmax and SUViso of the delayed image were more efficient than those of early images to classify lesions by the grade of tumors.
  • CONCLUSION: DTPI may be a better imaging method to grade the brain tumor than early imaging only.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479584.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


73. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors


74. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • MATERIALS AND METHODS: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down


75. Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D, Fisher DE, Patel A, Amin MB, Arbiser JL: Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med; 2007 Mar-Apr;13(3-4):160-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?
  • Angiomyolipomas are benign tumors of the kidney which express phenotypes of smooth muscle, fat, and melanocytes.
  • These tumors appear with increased frequency in the autosomal dominant disorder tuberous sclerosis and are the leading cause of morbidity in adults with tuberous sclerosis.
  • While benign, these tumors are capable of provoking life threatening hemorrhage and replacement of the kidney parenchyma, resulting in renal failure.
  • The histogenesis of these tumors is currently unclear, although currently, we believe these tumors arise from "perivascular epithelioid cells" of which no normal counterpart has been convincingly demonstrated.
  • Immunohistochemistry of human angiomyolipoma specimens revealed uniform staining of tumor cells, while renal cell carcinomas revealed positivity only of angiogenic vessels.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] Dev Biol. 1981 Apr 15;83(1):154-65 [7016634.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] Neuron. 1991 Aug;7(2):209-20 [1873027.001]
  • [Cites] Science. 1991 Oct 25;254(5031):571-3 [1658930.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Aug 21;68(2):193-201 [1394967.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1875-87 [7958863.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1888-96 [7958864.001]
  • [Cites] Hum Mol Genet. 1994;3 Spec No:1477-80 [7849741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11279-83 [7479979.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] J Neurosci Res. 1996 Feb 1;43(3):299-314 [8714519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15294-8 [8986805.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):810-5 [9529362.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):905-15 [10036240.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):295-9 [10088548.001]
  • [Cites] Development. 1999 Jun;126(11):2495-503 [10226008.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2869-74 [10383148.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21582-7 [16737956.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4739-49 [10574721.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28625-33 [10889192.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):963-71 [11032856.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):483-91 [11485907.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1541-54 [11583980.001]
  • [Cites] Dev Dyn. 2001 Oct;222(2):218-27 [11668599.001]
  • [Cites] FASEB J. 2002 Apr;16(6):586-8 [11919162.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):781-6 [12213705.001]
  • [Cites] Neurobiol Dis. 2003 Nov;14(2):279-90 [14572449.001]
  • [Cites] J Urol. 1986 Jun;135(6):1121-4 [3520013.001]
  • (PMID = 17592550.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R01 AR050727; United States / NIAMS NIH HHS / AR / P30 AR042687; United States / NIAMS NIH HHS / AR / R01AR 47901; United States / NIAMS NIH HHS / AR / R01 AR 050727; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  • [Other-IDs] NLM/ PMC1892760
  •  go-up   go-down


76. Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res; 2009 Aug 15;15(16):5032-5039
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves.
  • Significant morbidity can result from surgical treatment of these tumors.
  • Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2.
  • [MeSH-minor] Animals. Auditory Brain Stem Implants. Cochlear Implants. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Time Factors

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2002 Mar;20(3):475-82 [11836557.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):424-8 [17307835.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):332-9 [18285426.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1069-72 [17545869.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):978-86 [10215625.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):58-68 [18199958.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1063-71 [12066908.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Am J Otol. 1998 Sep;19(5):638-43 [9752973.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):577-81 [17726450.001]
  • [Cites] Stat Med. 1999 Aug 15;18(15):1905-42 [10532877.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 19671848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC009288
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS707923; NLM/ PMC4513640
  •  go-up   go-down


77. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


78. Vougioukas VI, Gläsker S, Hubbe U, Berlis A, Omran H, Neumann HP, Van Velthoven V: Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients. Childs Nerv Syst; 2006 Sep;22(9):1149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemangioblastomas are histologically benign lesions that occur sporadically or as a manifestation of von Hippel-Lindau disease (VHL).
  • The treatment strategy of these neoplasms is complicated by their unpredictable growth patterns and the often irreversible neurological deficits they may cause.
  • Ten patients were affected by von Hippel-Lindau and three were with sporadic tumors.
  • Two patients with brainstem tumors exhibited transient hemiparesis and caudal nerve palsy, respectively.
  • Preoperatively symptomatic patients with spinal tumors did not deteriorate nor improve after surgery.
  • During the observed follow-up periods, no tumor recurrences were observed.
  • Molecular screening of every pediatric patient and family is mandatory to enable the detection of extraneurological tumors and the development of an efficient therapeutic strategy.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Cerebellar Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adolescent. Brain Stem / pathology. Brain Stem / surgery. Cerebellum / pathology. Cerebellum / surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neurologic Examination. Postoperative Complications / diagnosis. Spinal Cord / pathology. Spinal Cord / surgery

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):82-94 [12546356.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):898-901 [1431953.001]
  • [Cites] J Med Genet. 1990 May;27(5):311-4 [2352258.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):24-30 [2909683.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17 (3):525-31 [8881249.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62 [10567493.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):695-8 [2586723.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):106-16 [12546358.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):257-60 [11835384.001]
  • [Cites] Neurosurgery. 1988 Mar;22(3):518-22 [3129668.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):321-7; discussion 327-8 [11504107.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):95-105 [12546357.001]
  • [Cites] Neurosurgery. 2003 Dec;53(6):1306-13; discussion 1313-4 [14633297.001]
  • (PMID = 16369852.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Sajja R, Barnett GH, Lee SY, Harnisch G, Stevens GH, Lee J, Suh JH: Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results. Technol Cancer Res Treat; 2005 Dec;4(6):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate tumor control, complications, and outcome from intensity-modulated radiation therapy (IMRT) for intracranial meningiomas.
  • Thirty-five patients with 37 lesions (35 benign and two atypical histology) were identified with a minimum of six months of radiologic follow-up for this retrospective review.
  • Twenty meningiomas (54%) were previously treated with surgery/radiosurgery prior to IMRT, and 17 meningiomas (46%) were treated with IMRT primarily after diagnosis was established by MRI/CT.
  • The median tumor dose was 50.4 Gy prescribed to the 87% isodose line providing a median target coverage of 95%.
  • A greater number of patients with longer follow-up after treatment may be needed to determine treatment variables predicting for long-term tumor control.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292888.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Nakamura M, Ishii K, Watanabe K, Tsuji T, Matsumoto M, Toyama Y, Chiba K: Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine (Phila Pa 1976); 2009 Oct 1;34(21):E756-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of the rarity of this tumor, there is no consensus on its optimal treatment options and prognosis.
  • The effects of surgical margins at surgery and postoperative radiotherapy on tumor recurrence and prognosis were investigated.
  • RESULTS: In 15 patients, total resection achieved (6 cases of en bloc resection without postoperative radiation, and in 9 cases piecemeal resection) was followed by whole brain and spinal cord radiation or local irradiation.
  • Fourteen of these patients survived without tumor recurrence.
  • In 1 case of total resection without radiotherapy, the tumor capsule was violated intraoperatively and local recurrence occurred 2 years after surgery.
  • In 4 patients, the tumors were removed subtotally.
  • Of these, 2 patients who received radiation (24 Gy) only to the whole brain and spinal cord developed recurrence, and 2 who received whole brain and spinal cord radiation (24 Gy) supplemented with local radiation (46 Gy) developed no recurrence.
  • Although this tumor is histologically benign, CSF dissemination can occur once tumor capsule is violated, before or during surgery.
  • Therefore, early diagnosis is essential, and a therapeutic strategy including radiotherapy, on the assumption that this tumor is malignant, should be established.
  • [MeSH-major] Cauda Equina. Ependymoma / surgery. Neurosurgical Procedures. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Incidence. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Prognosis. Radiotherapy, Adjuvant / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934795.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Salemi M, Calogero AE, Vicari E, Migliore E, Zaccarello G, Cosentino A, Amore M, Tricoli D, Castiglione R, Bosco P, Rappazzo G: A high percentage of skin melanoma cells expresses SPANX proteins. Am J Dermatopathol; 2009 Apr;31(2):182-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of SPANX (sperm protein associated with the nucleus in the X chromosome) gene family has been reported in many tumors, such as melanoma, myeloma, glioblastoma, breast carcinoma, ovarian cancer, testicular germ cell tumors, and hematological malignancies.
  • The expression of SPANX proteins was evaluated by immunohistochemistry in normal skin (n = 12), melanomas (n = 21), and benign nevi (n = 10), using a polyclonal antibody raised in our laboratory.
  • Benign nevi had an intermediate number of cells expressing SPANX proteins (25% +/- 8.5%), which resulted significantly higher than normal skin cells and significantly lower than skin melanoma cells.
  • In melanoma cells, the labeling was mostly nuclear, sometimes incomplete or limited to the perinuclear wall, even if cytoplasmic staining was also seen in SPANX-positive tumor cells.
  • [MeSH-major] Melanoma / metabolism. Nuclear Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies. Antibody Specificity. Biopsy. Epitopes / immunology. Epitopes / metabolism. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Multigene Family / physiology. Neoplasms / metabolism. Neoplasms / pathology. Nevus / metabolism. Nevus / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318807.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epitopes; 0 / Nuclear Proteins; 0 / SPANXA1 protein, human
  •  go-up   go-down


82. Soudack M, Guralnik L, Ben-Nun A, Berkowitz D, Postovsky S, Vlodavsky E, Engel A: Imaging features of posterior mediastinal chordoma in a child. Pediatr Radiol; 2007 May;37(5):492-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evaluation by CT revealed a low-density posterior mediastinal mass initially diagnosed as benign tumor.
  • We present our suggestions for preoperative evaluation of posterior mediastinal tumors.
  • [MeSH-major] Chordoma / diagnosis. Mediastinal Neoplasms / diagnosis. Mediastinum / diagnostic imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Child, Preschool. Cough / etiology. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Respiratory Sounds. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):743-6 [12972813.001]
  • [Cites] J Pediatr Surg. 1992 Dec;27(12 ):1515-8 [1469556.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):26-7 [8571897.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Jun;63(6):922-4 [5028681.001]
  • [Cites] Cancer. 1967 Nov;20(11):1841-50 [6061621.001]
  • [Cites] Hum Pathol. 1995 Dec;26(12):1354-62 [8522309.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Oct;8(7):781-6 [6665580.001]
  • [Cites] Skeletal Radiol. 1980;5(3):171-3 [7209569.001]
  • [Cites] J Pediatr Surg. 2002 Jan;37(1):50-6 [11781986.001]
  • [Cites] Childs Brain. 1981;8(3):198-206 [7238137.001]
  • [Cites] Skeletal Radiol. 2003 Jun;32(6):343-50 [12719927.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Apr;42(4):175-80 [12013671.001]
  • [Cites] Arch Pathol Lab Med. 1993 Sep;117(9):927-33 [8368907.001]
  • [Cites] J Fr Med Chir Thorac. 1961 Aug-Sep;15:623-31 [13873536.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Feb;23 (2):248-50 [12559357.001]
  • (PMID = 17345078.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Ashton-Sager A, Paulino AF, Afify AM: GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GLUT-1, a high-affinity glucose transporter, is normally expressed in erythrocytes, the perineurium of peripheral nerves, and capillary endothelial cells of the blood-brain barrier.
  • The purpose of this study was to evaluate the extent to which benign, hyperplastic, atypical, and malignant endometrial epithelia express GLUT-1.
  • GLUT-1 positivity increased in intensity as the distance of tumor cells to stroma increased.
  • The authors conclude that GLUT-1 is preferentially expressed in complex hyperplasia with atypia and in adenocarcinoma and that GLUT-1 immunostaining is useful in distinguishing benign hyperplasia from hyperplasia strongly associated with malignancy.
  • GLUT-1-mediated glucose transport may allow hypoxic tumor cells distant from stromal blood vessels to survive through glycolysis.
  • These data suggest that the expression of GLUT-1 transporter may be closely related to the malignant transformation of epithelial endometrial tumors by supporting their increased need for glucose metabolism.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785788.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1
  •  go-up   go-down


84. Campos WK, Linhares MN: Sporadic intramedullary spinal cord hemangioblastoma in a newborn. Pediatr Neurosurg; 2010;46(5):385-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemangioblastomas (HB) are rare lesions accounting for 2% of all spinal cord tumors.
  • They are highly vascular, benign tumors that occur either sporadically or in the presence of von Hippel-Lindau disease.
  • MRI of the spine revealed an intramedullary tumor extending from level T6 to T12.
  • RESULTS: The tumor was excised completely, using standard microsurgical techniques via a posterior approach.
  • The histological diagnosis was spinal cord HB.
  • CONCLUSION: A review of the literature revealed that this neoplasm is composed of 3 major cell types: endothelial cells, pericytes and stromal cells.
  • Complete microsurgical removal is the treatment of choice for spinal cord HB because the tumor is benign.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389752.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


85. Zhang H, Rödiger LA, Shen T, Miao J, Oudkerk M: Preoperative subtyping of meningiomas by perfusion MR imaging. Neuroradiology; 2008 Oct;50(10):835-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: This paper aims to evaluate the value of perfusion magnetic resonance (MR) imaging in the preoperative subtyping of meningiomas by analyzing the relative cerebral blood volume (rCBV) of three benign subtypes and anaplastic meningiomas separately.
  • The maximal rCBV (compared with contralateral normal white matter) in both tumoral parenchyma and peritumoral edema of each tumor was measured.
  • CONCLUSION: Perfusion MR imaging can provide useful functional information on meningiomas and help in the preoperative diagnosis of some subtypes of meningiomas.
  • [MeSH-major] Magnetic Resonance Angiography / methods. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):85-93 [16418363.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):119-23 [14686730.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] Acta Neurochir (Wien). 1994;129(1-2):31-8 [7998493.001]
  • [Cites] J Magn Reson Imaging. 2006 Oct;24(4):817-24 [16958061.001]
  • [Cites] Radiology. 2002 Apr;223(1):11-29 [11930044.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1306-15 [11498419.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1446-54 [15956514.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] Magn Reson Med. 1990 May;14(2):249-65 [2345506.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1554-9 [13679270.001]
  • [Cites] Neuroradiology. 1993;35(7):532-6 [8232883.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13 [14768726.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1015-21; discussion 1021-2 [1281915.001]
  • [Cites] Magn Reson Med. 1988 Feb;6(2):164-74 [3367774.001]
  • [Cites] Eur Radiol. 2002 Aug;12(8):2062-76 [12136325.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Eur Radiol. 2003 Apr;13(4):758-62 [12664114.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 18542938.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol; 2010 Dec;12(12):1278-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal.
  • Understanding the potential behavior of these tumors in individual patients is critical for rational therapeutic decision-making.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 6 / genetics. Histones / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):708-15 [12861068.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14 [14506147.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):939-43 [15375526.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1199-212 [16377562.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9113-26 [18258596.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] Mol Cancer. 2008;7:93 [19099607.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Biofactors. 2009 Mar-Apr;35(2):200-8 [19449449.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):409-20 [18637901.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1395-407 [19885562.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2584-93 [19847810.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • (PMID = 20685720.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones
  • [Other-IDs] NLM/ PMC3018937
  •  go-up   go-down


87. Kato K, Ujiie H, Higa T, Hayashi M, Kubo O, Okada Y, Hori T: Clinical presentation of intracranial epidermoids: a surgical series of 20 initial and four recurred cases. Asian J Neurosurg; 2010 Jan;5(1):32-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermoids are generally recognized as benign tumors; however, total resection is often difficult.
  • The recurrence from the residual capsule, dissemination of the tumor, and aseptic meningitis are common problems.
  • The location and size of the tumor, pre-and postoperative symptoms, adherence of the tumor to cranial nerves, and proliferative capacity were determined.
  • The most frequent site of the tumor was the cerebello-pontine (C-P) angle (16/24); eight of these patients presented with hearing loss and six presented with trigeminal neuralgia.
  • All epidermoids located in the C-P angle were attached to and/or compressed the trigeminal nerves, therefore, the origin is suggested to be the dura mafer of petrous bone around the trigeminal nerve.
  • Of all 24 patients, the tumor recurred in four (after 3, 5, 10 and 20 years).
  • One patient had a poor prognosis, with dissemination and brain stem infarction.
  • Epidermoids can recur from residual capsule adhering to the brain stem or cranial nerves up to 10-20 years after the initial surgery.
  • Long-term follow-up imaging studies are required when complete resection of the tumor capsule is not possible.
  • In rare cases, spontaneous cyst rupture, dissemination, and brain stem infarction result in a poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22028741.001).
  • [ISSN] 2248-9614
  • [Journal-full-title] Asian journal of neurosurgery
  • [ISO-abbreviation] Asian J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3198667
  • [Keywords] NOTNLM ; brain stem infarction / cerebello-pontine angle / epidermoid / malignant transformation / recurrence
  •  go-up   go-down


88. Larouche V, Huang A, Bartels U, Bouffet E: Tumors of the central nervous system in the first year of life. Pediatr Blood Cancer; 2007 Dec;49(7 Suppl):1074-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the central nervous system in the first year of life.
  • Among 1,289 infants identified from this literature review, the most common histological diagnoses are astrocytoma (30.5%), medulloblastoma (12.2%), ependymoma (11.1%), and choroid plexus tumors (11%).
  • Most tumors are supratentorial (65%).
  • The most important prognostic factors are histology (malignant vs. benign) and extent of resection.
  • Significant differences are noted for some tumor types by comparison with older children, for example in the aggressive behavior of low grade gliomas and the chemosensitivity of some high grade gliomas.
  • [MeSH-major] Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17943961.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


89. Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, Czerwenka K: Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep; 2006 Feb;15(2):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We then treated K562 leukemia cells with imatinib to analyze the effect of tyrosine kinase inhibition on CrkL activation. pCrkL expression was predominantly epithelial and detected in the majority of non-malignant prostate (79%), 49% of colon biopsies, 36% of skin biopsies, and 41% of samples obtained from normal brain.
  • In contrast to their corresponding benign tissues, pCrkL expression was significantly more common in breast cancer samples (49%, p<0.0001; Fisher's exact test), lung carcinomas (55%, p=0.0002), lymphatic tissues (80% vs. 10%, p=0.012), skin cancer (67%, p=0.020), ovarian malignomas (50%, p<0.0001) and colon carcinomas (63%, p<0.03).
  • We hypothesize that pCrkL is selectively up-regulated in a number of malignant tumor entities and involved in malignant transformation.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Biomarkers, Tumor / analysis. Neoplasms / drug therapy. Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / drug effects
  • [MeSH-minor] Benzamides. Blotting, Western. Cell Line, Tumor. Enzyme Activation / drug effects. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391854.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / CRKL protein; 0 / Nuclear Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


90. Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N, Vick NA: Growth rate of non-operated meningiomas. J Neurol; 2008 Jun;255(6):891-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Meningiomas are dural-based brain tumors that are typically histologically benign.
  • Volumetric measurement may be more accurate because tumors may grow in different directions than the planimetric axes.
  • METHODS: Twenty-one patients (with 22 tumors) had serial MRI brain scans available for review.
  • We reviewed the charts and measured tumor dimensions on the MRI scans.
  • Patient demographics, tumor location, and special radiologic characteristics (calcification, T2 hypointensity, dural tail, mass effect, and midline shift) were compared to the volumetric growth rate.
  • RESULTS: Patients included 17 females and 4 males; age at diagnosis 36 to 74 years (mean 61).
  • Most tumors were located in the convexity (27.27 %), sphenoid wing (27.27 %), or cerebellopontine angle (13.04 %).
  • There were no significant associations between other tumor locations, age, gender, or radiologic characteristics and volumetric growth.
  • CONCLUSIONS: The mean volumetric growth rate was significantly greater than the planimetric growth rate, suggesting that volumetric measurement conveys more information and is superior in assessing tumor growth.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / physiopathology. Meninges / pathology. Meninges / physiopathology. Meningioma / pathology. Meningioma / physiopathology
  • [MeSH-minor] Adult. Aged. Brain / pathology. Brain / physiopathology. Cell Proliferation. Cerebellopontine Angle / pathology. Cerebellopontine Angle / physiopathology. Cerebellopontine Angle / surgery. Cerebrum / pathology. Cerebrum / physiopathology. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neurosurgical Procedures. Retrospective Studies. Time. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):222-4 [7616265.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):507-11 [10898357.001]
  • [Cites] Neurology. 2004 Sep 28;63(6):1133-4 [15452322.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):545-7 [2398385.001]
  • [Cites] Neurology. 1997 May;48(5):1459-62 [9153494.001]
  • [Cites] Neurology. 1998 Dec;51(6):1718-20 [9855530.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):25-8 [10601396.001]
  • [Cites] Stroke. 1996 Aug;27(8):1304-5 [8711791.001]
  • (PMID = 18350353.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Nedzi LA: The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol; 2008 Oct;18(4):265-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice.
  • Retrospective published experience in functional and benign tumor radiosurgery is reviewed.
  • Prospective controlled clinical trials in ablative cancer therapy of early-stage lung cancer and metastatic disease in the brain, liver, and spine are reviewed.
  • [MeSH-minor] Brain / radiation effects. Humans. Neoplasms / radiotherapy. Nervous System Diseases / radiotherapy. Radiation Injuries / prevention & control. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725114.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


92. Fukushima S, Terasaki M, Sakata K, Miyagi N, Kato S, Sugita Y, Shigemori M: Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol; 2009;26(2):51-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-five initial histologically confirmed meningiomas (37 benign, 7 atypical, and 1 anaplastic) were reviewed according to current WHO criteria based on counting MF on HE-stained slides.
  • [MeSH-major] Histones / metabolism. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Mitotic Index / methods

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856215.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Histones; 0 / Ki-67 Antigen; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


93. Fulkerson DH, Luerssen TG, Hattab EM, Kim DL, Smith JL: Long-term follow-up of solitary intracerebral juvenile xanthogranuloma. Case report and review of the literature. Pediatr Neurosurg; 2008;44(6):480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile xanthogranuloma is a benign, non-Langerhans-cell histiocytic infiltrate that typically presents as a solitary cutaneous lesion in childhood.
  • There are reports of extracutanous involvement, including tumors in the central nervous system.
  • A solitary, intraparenchymal tumor without skin manifestations is a rare event, with only 3 prior cases reported in the literature.
  • Cerebral lesions have been associated with multifocal or systemic forms of the disease, with an occasionally fulminate clinical course.
  • Considering the rarity of this tumor, it is unclear whether patients need adjuvant therapy after excision of a solitary intraparenchymal tumor.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Diseases / surgery. Xanthogranuloma, Juvenile / diagnosis. Xanthogranuloma, Juvenile / surgery


94. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


95. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP: mTOR is activated in the majority of malignant melanomas. J Invest Dermatol; 2008 Apr;128(4):980-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, only 3/67 benign nevi (4%) were moderately positive, and none were strongly positive.
  • These data indicate that mTOR activation is very strongly associated with malignant, compared to benign, melanocytic lesions.
  • The proliferation of three melanoma-derived lines was blocked by the mTOR inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells. mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a farnesylation-dependent manner.
  • [MeSH-major] Melanoma / enzymology. Melanoma / pathology. Protein Kinases / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. DNA Mutational Analysis. Humans. Nevus / enzymology. Nevus / pathology. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Ribosomal Protein S6 / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914450.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


96. Fanburg-Smith JC, Auerbach A, Marwaha JS, Wang Z, Rushing EJ: Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases. Hum Pathol; 2010 May;41(5):653-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal chondrosarcoma, a rare malignant round cell and hyaline cartilage tumor, is most commonly intraosseous but can occur in extraskeletal sites.
  • Immunohistochemistry and follow-up were obtained on mesenchymal chondrosarcoma and tumor controls.
  • Twenty-two mesenchymal chondrosarcomas included 5 central nervous system (all female; mean age, 30.2; mean size, 7.8 cm; in frontal lobe [n = 4] and spinal cord [n = 1]) and 17 musculoskeletal (female-male ratio, 11:6; mean age, 31.1; mean size, 6.2 cm; 3 each of humerus and vertebrae; 2 each of pelvis, rib, tibia, neck soft tissue; one each of femur, unspecified bone, and elbow soft tissue).
  • The hyaline cartilage in most tumors revealed a consistent linear progression of chondrocyte morphology, from resting to proliferating to hypertrophic chondrocytes.
  • Mesenchymal chondrosarcoma demonstrates centrally located hyaline cartilage with a linear progression of chondrocytes from resting to proliferative to hypertrophic, which undergoes endochondral ossification, recapitulating growth plate cartilage and suggesting that this component of mesenchymal chondrosarcoma may be a differentiated (benign or metaplastic) component of a malignant metastasizing tumor.
  • Rare nuclear beta-catenin expression at the interface between hyaline cartilage and small round cells potentially implicates the APC/Wnt pathway during endochondral ossification in morphologically benign hyaline cartilage component of mesenchymal chondrosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Bone and Bones / pathology. Brain Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Hyaline Cartilage / pathology. Osteocalcin / metabolism. SOX9 Transcription Factor / metabolism. beta Catenin / metabolism


97. Messing-Jünger AM, Riemenschneider MJ, Reifenberger G: A 21-year-old female with a third ventricular tumor. Brain Pathol; 2006 Jan;16(1):87-8, 93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 21-year-old female with a third ventricular tumor.
  • On magnetic resonance imaging of the brain, she demonstrated a small contrast-enhancing mass in the posterior part of the third ventricle.
  • Intraoperatively, the tumor showed a close relationship to the choroid plexus of the third ventricle.
  • Histopathology revealed a benign schwannoma of World Health Organization grade I.
  • To our knowledge, only 9 cases of intraventricular Schwann cell tumors have been published so far.
  • Most of these tumors were benign schwannomas, except for 2 cases of malignant peripheral nerve sheath tumors.
  • The tumor of our patient is the first reported schwannoma of the third ventricle.
  • The origin of intraventricular Schwann cell tumors is unknown.
  • Histologically, intraventricular schwannoma needs to be distinguished from other spindle cell tumors, in particular pilocytic astrocytoma and fibroblastic meningioma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Neurilemmoma / pathology. Neurilemmoma / surgery
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612987.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


98. Gallina P, Buccoliero AM, Mariotti F, Mennonna P, Di Lorenzo N: Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course. J Neurosurg; 2006 Nov;105(5):736-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course.
  • OBJECT: Oncocytic meningioma has recently been recognized as a distinct morphological variant of intracranial meningothelial neoplasms, and only a few cases have been reported in the literature.
  • The first description of this lesion, which was based on data in six cases, revealed a potentially aggressive nature with a tendency to infiltrate the brain and to recur.
  • Histologically, the tumors were composed of sheets, nests, and cords of large polygonal neoplastic cells with finely granular cytoplasm.
  • Mitosis was also absent or exceedingly rare, and no brain cortex infiltration was observed.
  • At the last follow-up evaluation, all patients were asymptomatic and magnetic resonance imaging examinations demonstrated no evidence of tumor recurrence.
  • In fact, the histological features as well as the long-term favorable clinical course may suggest benign behavior of such neoplasms, as in the common forms of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Oxyphil Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121136.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


99. Kumar R, McClain D, Young R, Carlson GA: Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells. J Gen Virol; 2008 Jun;89(Pt 6):1525-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prion replication by conversion of benign PrPC isoforms into disease-specific PrPSc isoforms is intimately involved in prion disease pathogenesis and may be initiated in cholesterol-rich caveolae-like domains (CLD).
  • Elevation of ABCA1 in prion-infected brain is not a direct consequence of local PrPSc accumulation, indeed levels of ABCA1 are comparable in brain regions that differ dramatically in the amount of PrPSc.
  • [MeSH-minor] ATP Binding Cassette Transporter 1. Animals. Brain / metabolism. Cell Line, Tumor. Cholesterol / metabolism. Immunoblotting. Mice. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Feb;24(2):192-6 [10655069.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28634-40 [10893411.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15137-45 [11328826.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3158-66 [11073951.001]
  • [Cites] Nature. 2001 Aug 16;412(6848):739-43 [11507642.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5675-82 [11739375.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25457-64 [11994310.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48508-13 [12384498.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13244-56 [12547833.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14983-90 [14754889.001]
  • [Cites] Mol Biol Cell. 2004 Sep;15(9):4031-42 [15229281.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):556-64 [15369787.001]
  • [Cites] J Virol. 2004 Oct;78(20):11051-60 [15452225.001]
  • [Cites] Cell. 1990 Nov 16;63(4):673-86 [1977523.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):18217-23 [1680859.001]
  • [Cites] Nature. 1992 Apr 16;356(6370):577-82 [1373228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5690-4 [7911243.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):121-32 [7698979.001]
  • [Cites] Mol Med. 1994 Nov;1(1):19-30 [8790598.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14945-9 [8962161.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2333-8 [9122195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83 [9811807.001]
  • [Cites] Clin Microbiol Rev. 1999 Jul;12(3):429-44 [10398674.001]
  • [Cites] Mol Med. 1999 Jun;5(6):406-18 [10415165.001]
  • [Cites] J Clin Invest. 1999 Oct;104(8):R25-31 [10525055.001]
  • [Cites] Trends Cell Biol. 2005 Feb;15(2):102-11 [15695097.001]
  • [Cites] Mol Cell Neurosci. 2006 Feb;31(2):346-53 [16278084.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):527-33 [16373613.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 22;348(2):697-702 [16890918.001]
  • [Cites] J Neurochem. 2007 Aug;102(3):834-47 [17437544.001]
  • (PMID = 18474570.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS041997; United States / NINDS NIH HHS / NS / P01 NS041997-070001; United States / NINDS NIH HHS / NS / NS41997
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATP Binding Cassette Transporter 1; 0 / ATP-Binding Cassette Transporters; 0 / PrPC Proteins; 0 / PrPSc Proteins; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ NIHMS115814; NLM/ PMC2706533
  •  go-up   go-down


100. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology; 2007 Oct;27(5):407-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
  • We investigated the utility of cell proliferative indicator in the evaluation of histologically benign meningiomas.
  • We selected 25 benign non-recurrent meningiomas, 15 benign recurrent meningiomas after complete surgical resection, 30 atypical meningiomas, and 15 anaplastic meningiomas out of 384 cases studied.
  • There was no dependable histological parameter to predict recurrence among benign-looking meningiomas.
  • The mean MIB-1 HLI values +/- SD were 3.47 +/- 2.0% for benign meningiomas, 5.08 +/- 4.0% for atypical meningiomas and 11.66 +/- 7.06% for anaplastic meningiomas.
  • In comparison, the mean MIB-1 HLI of benign non-recurrent meningiomas were 2.66 +/- 1.7% and with recurrence were 4.21 +/- 2.78% (P = 0.0339).
  • Using receiver operating characteristic, it was seen that neoplasm recurred with the MIB-1 HLI of > 2.6 having the sensitivity of 64.6% and specificity of 68% among benign (grade I) meningiomas.
  • MIB-1 positive tumor cells were maximally aggregated at the periphery of excised specimen.
  • MIB-1 HLI, integrated with standard histopathology can provide better information about the disease biological nature in benign meningiomas.
  • [MeSH-major] Biomarkers / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Brain Neoplasms / pathology. Humans. Mitotic Index. Neoplasm Invasiveness. Probability. Recurrence. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018472.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down






Advertisement